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Abstract 
Obesity is well-documented to promote the development of nonalcoholic fatty 
liver disease (NAFLD) including its more advanced stages such as non-alcoholic 
steatohepatitis, cirrhosis and hepatocellular carcinoma (HCC). While metabolic 
perturbations describing obesogenic progression from NAFLD to HCC have 
largely been investigated, our knowledge of the role lipolysis plays in this process 
is scant. This research project is aimed at understanding the role fasting lipid 
metabolism plays in pathologic features of carcinogenesis as well as 
synergistically combining with lifestyle factors to prevent obesity driven 
progression of NAFLD to HCC. To elucidate these features, we employed two 
seminal studies. The first study characterized the role of adipose triglyceride 
lipase (ATGL) in limiting a major cell cycle regulator, cyclin D1, and 
hepatocellular proliferation both in vitro and in vivo. We show that lipid catabolism 
via ATGL antagonizes cell proliferation. Additionally, we recapitulate these 
findings using a partial hepatectomy model to drive hepatocellular proliferation in 
vivo.  
In the second study, we conduct a long-term carcinogenesis study that examines 
the role of dietary fat composition and lifestyle factors that promote fasting lipid 
metabolism. Animals were calorically restricted (CR) or exposed to regular 
endurance exercise. Using the hepatic carcinogen diethylnitrosamine (DEN), we 
show CR prevents hepatic tumor formation independent of dietary fat 
composition. RNA sequencing of non-transformed liver tissues revealed changes 
in metabolic pathways and reduced inflammation, cytokine production, stellate 
vi 
cell activation and migration, and genes associated with liver injury and 
oncogenesis. Taken together, fasting hepatic lipid metabolism plays a significant 
role in mitigating proliferative effects often associated with overconsumption of 
calories. Furthermore, lifestyle factors that promote lipolysis in the liver robustly 
protected mice from developing tumors. Further investigation is warranted to 
define the molecular mechanisms ATGL plays in limiting hepatic proliferation as 
well as characterizing the role of ATGL and fasting in hepatic tumorigenesis.  
vii 
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CHAPTER 1 
 
An Overview of the Epidemiologic, 
Metabolic, and Cell Signaling Events 
Associated with Obesity Driven 
Hepatocellular Carcinoma 
 
 
 
 
 
 
 
 
Jonathan Ploeger wrote this chapter in its entirety  
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Global Impact of HCC 
Introduction 
The World Health Organization reports economic costs of treating cancer topped 
$1.16 trillion dollars in 2010, and projects worldwide incidence to jump 57% in the 
next 20 years (1). Of those cases, primary liver cancers are the fifth most 
common cancers worldwide and Hepatocellular Carcinoma (HCC) accounts for 
between 85-90% of primary liver cancers (2). Additionally, HCC is one of the 
most deadly forms of cancer worldwide with more than 700,000 cases diagnosed 
annually and greater than 600,000 of those cases resulting in death (3). 
Historically, developed countries including the United States have experienced 
low incidences of HCC, with more than half of all cases occurring in African and 
Asian countries. However, over the past decade incidence rates in the U.S. have 
tripled and are expected to continue trending upward in the coming years (4). 
Currently, HCC deaths in men are rising faster than any other cancer-related 
death in the United States (2). 
 
Epidemiology of HCC & its Precursors 
HBV/HCV & HCC 
Hepatitis B (HBV) and Hepatitis C (HCV) viral infections remain the largest 
contributors globally to HCC respectively, contributing in the upwards of 84% of 
incident cases (3). As would be expected, HBV and HCV share a number of 
similarities and disparities as it pertains to the etiology of HCC. Both contribute to 
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chronic hepatic injury resulting in fibrosis and ultimately cirrhosis leading to 
pathogenesis of HCC. Furthermore, both HBV and HCV contribute to HCC 
through multiple oncogenic mechanisms including DNA methylation, proliferation 
promotion, increased ROS, and impaired autophagy (5). In addition, both viruses 
share similar risk factors that result in increased incident odds of HCC 
development: co-infection with HBV/HCV, alcohol use, male gender, HIV, 
diabetes mellitus, older age, African American race, esophageal varices, and 
smoking (3). However, whereas HCV is an RNA virus, HBV is a DNA virus, which 
allows its integration into the host genome where it can induce oncogenic 
mutations of host DNA (6). Furthermore, HBV accounts for the majority of 
worldwide HCC cases and does so in developing countries more often. A major 
contributing factor in HBV related HCC cases is aflatoxin exposure. One such 
report estimated the risk of liver cancer in HBV infected individuals exposed to 
aflatoxin to be 30 times greater than unexposed (7). Interestingly, in recent years 
incidence rates of HBV related HCC have declined in part due to effective 
vaccination programs and limited exposures to aflatoxin (8).   
Conversely, developed countries have tended to associate the majority of HCC 
cases with HCV infection. For example, HCV once accounted for 40-60% of HCC 
cases in the United States despite only accounting for 30% of cases worldwide 
(9). However, safer procedures in blood transfusion and reductions in IV drug 
use have lowered incidences of HCV related HCC cases (3). Intriguingly, the 
reduction HCV has not resulted in an overall trend decrease in HCC. On the 
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contrary, cases of HCC have continued to rise over the past decade (4). This 
trend has led researchers to consider other etiologies of HCC.  
NAFLD & HCC 
First characterized in 1980 (10), non-alcoholic Fatty Liver Disease (NAFLD), as 
the name suggests, is a disease characterized by excessive fatty infiltration of 
the liver in non-alcohol users. If left unchecked, the overload of lipid increases 
inflammation of the parenchymal portal regions and organ damage, which leads 
to development of non-alcoholic steatohepatitis (NASH). The spectrum of NAFLD 
is the most common cause of liver disease in developed countries (11). 
Estimates from population sampling suggest 20-30% of Western country 
inhabitants have NAFLD (12). In addition, diagnosis of NAFLD is linked to greater 
mortality than the general population, with the majority of death resulting from 
liver diseases including HCC (13). Unlike incident rates of HCV/HBV in 
developed countries, rates of NAFLD/NASH continue to increase, largely as a 
result of their association with obesity and metabolic syndrome. Additionally, 
NAFLD/NASH as comorbidities with increasing age, the male sex, and type-2 
diabetes (T2D) are well-established risk factors for the development of HCC (12). 
Although a recent prospective U.S. population study concluded a greater 
incidence of HCC from HCV related cirrhosis compared to NAFLD derived 
cirrhosis (14), the contrasting prevalence of HCV and NAFLD provides reason for 
concern. In fact, contrary to the previous study, a case control study found that 
when comparing cryptogenic cirrhosis (CC) to HCV related cirrhosis, CC patients 
were more likely to have obese BMI’s, T2D, and elevated serum triglycerides 
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(TAG), all well-established risk factors for NAFLD and HCC (15). Taken together 
there is increasing data suggesting that NAFLD may become the primary source 
of HCC in the near future (2). Previously, it was thought NAFLD contributed to 
HCC through its progression to NASH which has a greater risk for progression to 
cirrhosis, with the first reported case of HCC derived from cirrhotic related 
NAFLD in 1990 (16). However, a number recent studies report HCC 
development in non-cirrhotic NAFLD (17). 
In the past decade 116 cases of HCC have been histologically confirmed as 
derived from NAFLD without cirrhosis, which represents greater than 30% of all 
NAFLD resultant HCC cases (17). Additionally, the first reported case of NASH-
associated HCC was reported as recently as 2005 (18). Increasing trends of 
advanced onset of HCC give reason for concern in developed countries including 
the U.S. For example, a case report conducted by Kawada et al. (19) using strict 
histological evaluation criteria to diagnosis NASH confirmed 75% of examined 
cases of NASH-related HCC did not show signs of cirrhosis. However, the 
authors report a potential for bias as the study population were all surgical 
resection patients. However, a number of other case reports have produced 
similar results leading to the conclusion that degree and severity of 
NAFLD/NASH risk factors may contribute to HCC (18, 20, 21). 
Ultimately one of the greatest obstacles in gaining a deeper understanding of the 
role NAFLD plays in the development of HCC is obtaining accurate reporting. 
Because most patients present clinically at the point of cirrhosis, a point at which 
evidence of fatty infiltration has dissipated, it is suggested that NAFLD 
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associated cases of HCC are grossly under reported (17). Thus, while some 
prospective data suggests incidence of NASH related HCC is low or absent (22), 
the majority of evidence suggests NAFLD is primarily responsible for cases of 
CC. Such evidence was reported in a prospective study from the U.S. in which 
CC was the second leading etiologic factor to HCC only behind HCV. The study 
found clinical or histopathologic features of NAFLD in 50% of CC cases (23). 
Furthermore, a retrospective analysis concluded that features of NASH are more 
commonly found in HCC cases linked to CC (15). Despite HCV being an 
important etiologic factor in the global burden of HCC, NAFLD has established 
itself as a major risk factor in developed countries. Given the correlation between 
NAFLD and obesity, it is no surprise obesity is also strongly linked to HCC. 
 
Obesity & HCC 
Contrariwise to reducing trends in HCV, the United States is currently faced with 
an epidemic of obesity and obesity related diseases. In 2008, there were over 1.4 
billion overweight individuals worldwide, with nearly 500 million of those being 
obese (24). Currently, the prevalence of obesity is greater than 35% in U.S. adult 
populations (25) and rates have increased between 2-3 fold over the past 3 
decades in children (26). It is currently well-accepted that as obesity increases, 
so too does the risk of cancer in general and more specifically, liver cancer. 
Obesity has been estimated to be directly related to 14% and 20% of all cancer 
diagnoses in U.S. men and women, respectively (27). Obesity is particularly 
relevant to HCC because of its contributions to NAFLD. A prospective cohort of 
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over 28,000 Swedish men and women conducted by Wolk et al. (28) describes a 
33% increase in the incidence of all cancers and a 3.6 times greater incidence of 
liver cancer in obese subjects compared to non-obese. In another large cohort 
conducted in the U.S., mortality rates from cancer paralleled increasing quintiles 
of BMI (29). In that same study liver cancer also showed a similar trend with a 
4.52 greater risk of death in the highest BMI group compared to baseline quartile. 
Two recent reviews further corroborated these studies and confirm the 
association between obesity and HCC (30, 31).   
Although generalized obesity has been demonstrated as an independent risk 
factor to NAFLD associated HCC, visceral adiposity appears to be a more 
accurate predictor. A number of recent studies, including a large prospective 
population study in Taiwan, have demonstrated an increased risk of NAFLD, 
HCC diagnosis and HCC reoccurrence in individuals with greater central 
adiposity (32–35). Visceral fat accumulation is thought to largely contribute to the 
pathogenesis of HCC due to the increased TAG burden placed on hepatocytes, 
particularly in the portal vein region. This increased intercellular fat burden is 
thought to cause excess endoplasmic reticulum (ER) stress which, leads to 
aberrations in cell signaling progressing the liver to NAFLD, fibrosis and 
ultimately carcinogenesis (36). Despite its contributions to fatty liver and HCC, 
obesity by itself does not fully explain NAFLD & HCC; nor can it solely account 
for the rapidly increasing prevalence of hepatic carcinogenesis seen in Western 
countries.   
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T2D & HCC 
Along with obesity rates for typeT2D have increased exponentially over the past 
decade. Increased diagnostic rates of T2D and obesity in the U.S. from 1994-
2010 have been well established (37). Interestingly, the results demonstrate that 
not only have both rates increased, but that they have increased in a paralleled 
manner. Furthermore, Information from the National Diabetes Statistics from the 
NIH estimates that 8.3% of the U.S. population has T2D (38). The rate of 
diagnosis for T2D alone is staggering, with total annual treatment costs reaching 
$174 billion (38). However, in accordance with the rise of obesity, T2D has also 
been linked to HCC (21, 39–42) and the association is further complicated when 
considering HCV (43). However, whereas obesity is a risk factor for NAFLD 
development and as a result an increased risk for HCC, T2D is thought to have a 
more unique relationship with HCC risk. 
Loria et al. (44) propose a mechanism whereby genetic and lifestyle factors (e.g. 
obesity) lead to initial insulin resistance (IR). IR then contributes to NAFLD, which 
along with β-cell destruction leads to development of T2D. Finally, uncontrolled 
T2D in the setting of NAFLD increases risk for NASH and ultimately HCC. This 
theory falls in line with the “two-hit hypothesis” of NAFLD development where the 
first hit involves accumulation of TAG and steatosis as a consequence of IR. The 
second hit is long-term consequences of fat accumulation leading to necrosis 
and fibrosis which, ultimately results in the development of HCC (45). Indeed, 
evidence supports the importance of IR as a predictor of NAFLD independently 
of β-cell function (46, 47). Furthermore, a number of cross-sectional studies 
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support NAFLD as a risk factor for T2D (48, 49) with temporality supported by 
prospective studies (50–52). Consistent with the “two-hit hypothesis,” T2D 
derived from NAFLD has been associated with an increased risk for development 
of hepatic fibrosis (53) and ultimately has abidingly been linked to increased risk 
for HCC both in cirrhotic (39–42) and non-cirrhotic livers (54, 55). 
The increased incidence of HCC in developing countries despite the positive 
strides made in controlling HBV/HCV outbreaks is alarming. The last decade has 
provided great insight in establishing strong connections between uncontrolled 
metabolic dysfunction and the development of HCC. Given the increasing 
evidence of metabolic perturbations in cancer cells, these epidemiologic 
relationships have drawn more recent attention in elucidating metabolic as well 
as molecular mechanisms that can explain the progression leading to NAFLD as 
well as in HCC. 
 
Metabolic Alterations in HCC 
Introduction 
The elegant organization in the metabolism of nutrients to sustain cellular and 
organismal homeostatic function is quintessential in the sustainment of life. 
Despite the many intracellular redundancies aimed towards maintaining 
metabolic balance given a variety of external circumstances, many disease 
states require reprogramming of cellular metabolic function in order to thrive. 
These perturbations, while seemingly inefficient, often allow diseased cells to 
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bypass feedback regulation, alter cell signaling, and provide metabolic 
intermediates necessary to sustain survival even at the expense of the organism. 
The thought of cancer as a purely genetic disease was challenged as far back as 
1924 by German biochemist Otto Warburg (56). However, it has not been until 
more recently that Warburg’s theories as well as other metabolic alterations have 
been more extensively studied. These investigations have provided a litany of 
new information, hallmarking metabolic alterations in cancer development and 
proliferation. 
 
Glucose Metabolism 
Postprandial carbohydrate and gluconeogenic glucose is catabolized by target 
tissues, eventually generating 36 ATP for every molecule of glucose consumed 
through oxidative phosphorylation. In addition to ATP production, glucose can be 
converted to glycogen and stored for later energy production in times of fasting. 
These processes are well regulated by feedback mechanisms that limit influx of 
glucose when sufficient ATP is produced. However, the generation of ATP 
requires the cell to have sufficient cellular oxygen levels. In humans, if the 
cellular environment becomes hypoxic, pyruvate from glycolysis is fermented to 
lactate generating two ATP. In healthy cells, the replenishment of cellular oxygen 
inhibits further glucose fermentation in a process known as the Pasteur effect 
(57).  
Despite these feedback mechanisms, Warburg discovered that cancer cells 
preferentially ferment glucose to lactate independently of intracellular oxygen 
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levels, or aerobic glycolysis, otherwise termed the Warburg effect (58). While this 
discovery led to many further metabolic discoveries in the context of cancer, 
Warburg’s original theory was that cancer cells ferment glucose due to impaired 
mitochondrial function. This idea however, has been challenged (59) and in fact 
cancer cells rely on mitochondrial function to generate carbon intermediates for 
de novo lipogenesis (60) and amino acid synthesis (61, 62). Thus, while 
metabolic differences of healthy and cancer cells are fairly well characterized, 
they do not fully explain oncogenic transformation and resultant rapid 
proliferation. 
Most multicellular organisms are offered an abundant nutrient rich environment.  
Therefore, without additional regulatory mechanisms most cellular environments 
would experience rapid and uncontrolled proliferation.  To combat these 
deleterious changes, cells regulate nutrient uptake through growth factors.  The 
requirement for growth factor presence to elicit proliferation, differentiation, and 
carcinogenesis has been well documented (63). Previously it was thought cancer 
cells must overcome growth factor dependence through genetic mutations that 
alter receptor-signaling pathway initiation.  However, recent research has pointed 
to a “seed and soil” hypothesis, wherein overnutrition provides a 
microenvironment producing excessive levels of growth factors, which activate 
downstream targets such as protein kinase B (Akt) and mechanistic target of 
rapamycin (mTOR), ultimately producing a feed forward cycle resulting in 
uncontrolled proliferation (64). This mechanism has been well documented in a 
number of tissues (65–68) including the liver (66, 67). Despite the current model 
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that overnutrition contributes to rapid proliferation through altered growth factor 
presence, aerobic glycolysis is metabolically much less efficient than oxidative 
metabolism. Taken together, this means that aerobic glycolysis must 1) produce 
enough ATP to maintain cellular viability, and 2) provide metabolic products and 
byproducts used for continued proliferation to be considered a viable and 
sustainable alternative to oxidative metabolism. 
Aerobic glycolysis is nearly 20 times less efficient regarding ATP production than 
oxidative metabolism. This process appears unsustainable for numerous 
reasons, one being maintenance of sufficient cellular ATP, as cells void of 
sufficient ATP often undergo apoptosis (69). Yet, cancer cells preferentially utilize 
fermentation and thrive despite its limitations. In demonstrating how this process 
maintains feasibility, Kilburn et al. (70) showed that the basal level of ATP 
necessary for cellular maintenance is far above that required for growth and 
division. Furthermore, increased glucose transport into cancer cells exceeds the 
bioenergetic demand for growth and proliferation achieved through aerobic 
glycolysis as demonstrated by high ATP/ADP ratios, even under circumstances 
of rapid cell division (71).  
One clue into the ability of cancer cells to regulate the production of ATP 
considering increased glycolytic activity, lies in the observation that rapidly 
dividing cells also exhibit altered cell signaling. The phosphoinositide 3-kinase 
(PI3K) signaling pathway is perhaps the most well characterized pathway in 
glucose and growth. PI3K signaling controls and regulates amino acid 
metabolism in cancer via mTOR (72), lipid synthesis as well aspects of glucose 
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metabolism including glucose uptake (73) and increased activity of hexokinase 
(74) and phosphofructokinase (75). In addition, the penultimate step in glycolysis 
that catalyzes the generation of one molecule each of ATP and pyruvate is 
regulated by pyruvate kinase (76). Pyruvate kinase has four mammalian isoforms 
(L, R, PKM1, PKM2), of which the M1 isoform is expressed in adult tissues (71). 
Conversely, the M2 isoform is most widely expressed during embryonic 
development (77). However, what makes the M2 isoform necessary for 
embryonic growth and development is also ideal in cancer growth and 
proliferation (71). In contrast to the M1 isoform, PKM2 is regulated by tyrosine 
kinase signaling (78). In response to tyrosine kinase activity PKM2 is induced 
into a low activity state, diverting carbon to biosynthetic pathways and away from 
catabolic mitochondrial metabolism (78, 79). Furthermore, these studies have 
also demonstrated the necessity of PKM2 for continued cancer cell survival. 
Aerobic glycolysis has become the most well characterized metabolic 
perturbation in cancer. Warburg’s seminal work has laid a foundation from which 
numerous important works have been crafted. Such studies have demonstrated 
a biological explanation for glucose sensitivity in several cancer cells of varying 
etiology and tissue specificity (80). Furthermore, evidence has grown indicating 
the cross-talk between signaling pathways and metabolic regulation important for 
glucose metabolism. More importantly, elucidation of aspects in glucose 
metabolism and cell signaling in cancer has established the overreaching 
importance of aerobic glycolysis in driving the biosynthetic aspects of other areas 
of metabolism.   
14 
Protein Metabolism 
Recent years have explicated amino acids (AA) as multifarious molecules, 
contributing to cellular functions beyond cell signaling. Essential amino acids are 
defined as those which cannot be derived de novo and therefore, must be 
acquired from exogenous sources. Conversely, non-essential amino acids 
(NEAA) are those which can be attained from exogenous or endogenous 
sources. Interestingly, there is growing evidence that besides their role as 
building blocks of proteins and polypeptides, certain AA play a larger role than 
once thought in the regulation of key metabolic pathways that are necessary for 
cellular maintenance, growth, and proliferation; they are called functional or 
conditionally essential AA  and include arginine, cysteine, leucine, proline, 
tryptophan, and most relevantly to cancer glutamine (81).  
Alterations in glucose involved metabolism and cell signaling in cancer cells 
noted by Warburg and others has provided important insights to other areas of 
nutrient metabolism in oncogenesis. The cellular demand for glutamine in cancer 
was established as early as 1955 (82). However, it has not been until more 
recently that metabolic and biochemical studies have demonstrated that 
increased glycolytic function cannot by itself sustain growth and proliferation and 
indeed requires other nutrients such as AA. The amino acid glutamine 
contributes to core metabolic tasks of proliferating tumor cells. For example, 
glutamine provides substrate for cellular bioenergetics (83), supports defenses 
against oxidative stress (83, 84), and complements glucose metabolism in the 
production of biomass (85). Collectively, the diverse contributions of glucose and 
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glutamine metabolism paint a more complete picture of oncogenic growth and 
proliferation. 
Conventionally glutamine’s contributions to cellular function are limited primarily 
to contributing to nitrogen stores. However, during rapid growth and proliferation 
the cellular demand may exceed synthesis by 10-fold, making glutamine a 
conditionally essential AA (86). Growing cancer cells require the generation of 
NEAA for the biosynthesis of proteins and nucleotides as well as for continued 
generation of ATP (85). Much of this demand is met through the marked increase 
in glutaminase, the enzyme that catalyzes glutamine to glutamate (87). The 
nitrogen generated from the glutaminase reaction is allocated to various pools for 
the generation of NEAA; alanine and aspartate are particularly generated and 
have been targeted as biomarkers of cancer (88). Both NEAA are readily utilized 
in protein synthesis; aspartate also contributes to nucleotide synthesis as well as 
provides electron donation to complex I of the electron transport chain leading to 
ATP generation through its contribution to the malate-aspartate shuttle (76, 86). 
Glutamine also directly contributes to purine and pyrimidine synthesis (89). The 
γ-nitrogen from glutamine are added to growing purine rings as well as contribute 
to the conversion of xanthine monophosphate to guanosine monophosphate 
(86). 
Reactive oxygen species (ROS) are produced from normal cellular respiration 
and metabolism, but can have deleterious consequences when homeostasis is 
not maintained. One consequence of increase ROS generation is mitogenesis 
(90). However, another consequence of increased ROS is the induction of 
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apoptosis (91). Therefore, cancer cells like their non-transformed counterparts 
must balance the production of ROS to survive; glutamine metabolism plays a 
role in maintaining this balance. Besides aspartate and alanine, cysteine is 
generated from the glutamate pool derived from glutamine metabolism (76). 
Cysteine is derived from an antiporter system in which, glutamate is exported 
from the cell while cysteine is imported. Following importation, cysteine is 
converted to cysteine using intercellular glutamate, ultimately producing 
glutathione (GSH), a major balancer of ROS that has been targeted for cancer 
therapy (92).   
While glutamine metabolism is essential to cancer cells in the generation of 
nucleotides, proteins and antioxidants, the metabolic efficiency of glutamine 
exceeds these demands. Additionally, since the PKM2 isoform drives 
fermentation of glucose, alternative metabolites are required for cellular energy. 
Therefore, glutamine sustains the mitogenic environment by providing ATP and 
reducing equivalents. After the conversion of glutamine by glutaminase, 
glutamate acts as a respiratory substrate through further conversion of its carbon 
backbone to α-ketoglutarate. Once committed to glutaminolysis through the TCA 
cycle, glutamate has a number of fates and may be oxidized to malate and 
shuttled out of the mitochondria to form pyruvate which, can be shuttled back into 
the mitochondria to form acetyl-Coenzyme A (Ac-CoA), making glutamine a 
major anaplerotic substrate in cancer metabolism (85, 93). Important to note of 
this process is the contribution to cellular energetics; as α-ketoglutarate is 
converted to succinyl-CoA, NADH is produced which is utilized by complex I of 
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the electron transport chain, ultimately producing ATP. Furthermore, the 
conversion of malate to pyruvate by malic enzyme produces NADPH, reducing 
equivalents used in growth, proliferation, and energy production (85). However, 
DeBerardinis et al. (89) have noted that much of glutamine’s carbon is exported 
from the mitochondria as lactate, adding to the pool from aerobic glycolysis (89). 
Finally, glutamine may also be exported from the mitochondria as citrate, which 
can be converted to oxaloacetate, then malate, and finally pyruvate generating 
NADPH while contributing to anaplerosis or the citrate may be used for another 
metabolic hallmark of cancer cells: de novo lipogenesis (60, 93). Nonetheless, 
under hypoxic conditions this process can be reversed through what is termed 
reductive glutamine metabolism, via isocitrate dehydrogenase-1 (IDH-1) (60). 
In addition to metabolic contributions glutamine has been established as a driving 
force in cancer cell survival and growth. In fact, cellular glutamine uptake has 
recently been shown to be the rate-limiting step necessary for the EAA and 
growth factor regulation of mTOR complex 1 (mTORC1) (94). These findings are 
unsurprising given that glutamine and ATP levels are inversely related. 
Therefore, as ATP levels decrease, AMPK levels rise.  Increasing levels of 
AMPK trigger mediators of autophagy (95). Furthermore, AMPK phosphorylates 
tuberous sclerosis complex 2, inhibiting mTORC1 and stunting growth and 
proliferation (95). Conversely, the presence of growth factors and a nutrient rich 
environment, particularly glutamine, drives the activation of mTOR complex 2 
(mTORC2) and mTORC1, respectively (94, 96). The activation of mTORC1 leads 
to downstream phosphorylation and activation of ribosomal protein S6 kinase 
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(S6K) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), 
which stimulates translation, ribosomal biogenesis, and cell growth (96).  
While it has been well-established that cancer cells massively increase utilization 
of various macro and micro-nutrients in carbohydrate and protein metabolism, 
increasing evidence supports the notion that nutrient excess drives the 
oncogenic activation (97). Collectively, glucose and glutamine metabolism work 
synergistically to regulate a number of processes required of proliferating cells. 
Interestingly, while glucose and glutamine metabolism drive various aspects of 
growth and proliferation individually, the metabolic processes of each also 
contribute to the sustainment of each other. This fact remains true in an 
additional hallmark of cancer metabolism: de novo lipogenesis.  
 
Lipid Metabolism 
Introduction 
Cancerous cells must maintain metabolic efficiency to maintain growth and 
proliferation. Given the reliance on amplified uptake and subsequent altered 
metabolism of glucose and glutamate, it is no surprise that a need for cataplerotic 
events is necessary for maintaining oncogenic metabolic homeostasis. De novo 
lipogenesis (DNL) is one such cataplerotic event that is increased in cancer (98). 
However, while oncogenic alterations of metabolism are predominantly universal 
from tissue to tissue and etiology to etiology, lipid metabolism has a unique role 
in these respects as it relates to oncogenesis. It is well understood that the liver 
is a major organ for FA trafficking in the human body. FAs derived within the liver 
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primarily arrive from FFA uptake, chylomicron remnant uptake, and/or DNL. 
However, cancer cells favor amplification of de novo synthetically derived FAs 
over exogenous uptake (98). Unlike aerobic glycolysis and glutamine metabolism 
which are universal perturbations in oncogenic metabolism, DNL provides a 
mechanistic explanation to the recently increasing development of HCC via 
NAFLD. Previous studies have demonstrated that DNL accounts for ~8% of 
hepatic FAs during fasting, but increase to 27% post-prandially (99). 
Interestingly, intrahepatic TAG derived from DNL mirrors post-prandial levels in 
patients with NAFLD (100) and liver cancer (101). 
 
De Novo Lipogenesis in Cancer 
Regardless of the source of derivation, FAs must be “activated” by long-chain 
fatty -acyl-CoA synthetase (ACSL) by ligating acyl-CoA to FA in forming FA-Acyl-
CoAs for sequestration into the cell and for access into the bioactive pool (102). 
Several isoforms of ACSL exist with ACSL3 and ACSL5 being most prominent in 
hepatic tissue (103) and have been identified as essential to lipid droplet (LD) 
formation in HCC cell lines (104). Acetyl-CoA carboxylase (ACC) and fatty acid 
synthase (FAS) sequentially carry out the committed steps of DNL converting 
acetyl-CoA to malonyl-CoA and FAs respectively. However, ACC has cytosolic 
and mitochondrial isoforms, ACC1 and ACC2, respectively. While ACC1 is most 
commonly associated with DNL, its targeted hepatic ablation increases ACC2 
activity accordingly, making it necessary but not sufficient in maintaining DNL 
(105). Malonyl-CoA produced by ACC1/2 provides substrate for elongation by 
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FAS that terminates upon the generation of palmitate (16:0) (106). Further 
elongation of hepatic 16:0 is primarily carried out via long-chain fatty acid 
elongase (ELOVL) 5, which produces mostly oleate (18:1) (107). Additionally, 
stearoyl-CoA desaturase (SCD)-1 generates palmitoleate (16:1) and oleate 
(18:1), while longer chain FAs are derived from the action of other elongase 
enzymes such as ACSL. The ACSLs are responsible for eventual incorporation 
of FAs into TAG and phospholipids; their dysregulation is an important indicator 
of altered DNL realized in HCC (108). 
Increased TAG formation is known to accompany DNL. Dysregulation of lipid 
metabolism resulting in excess TAG within hepatic LDs is a hallmark of NAFLD 
(109), independent of liver injury (110), and its progression to HCC (108). The 
initial step of de novo TAG synthesis is carried out by the enzyme sn-1-glycerol-
3-phosphate acyltransferase-1 and produces lysophosphatidic acid (111). This 
enzyme is a key contributor to excessive hepatic TAG accumulation and its 
deletion has been associated with reduced susceptibility to HCC (112). 
Conversely to newly synthesized FAs, sn-1,2-diacyglycerol acyltransferase-2 
(DGAT2) esterifies diacylglycerol to TAG from de novo sources whereas DGAT1 
esterifies FAs from exogenous sources. Overexpression of DGAT2 is sufficient to 
drive steatosis independently of IR (113). Moreover, these enzymes have been 
targeted in cancer therapy and inhibition of the DGATs has proved effective in 
ablating TAG synthesis in the human liver cancer cell line HepG2 (114). In 
addition to the DGATs, monoacylglycerol acyltransferases have also been 
implicated in NAFLD (115).   
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Clinical Implications of Lipid Metabolism and HCC 
Clinically important, a single nucleotide polymorphism (I148M) of the gene 
patatin-like phospholipase domain containing A3 (PNPLA3) has been identified 
as a predictor of NAFLD (116) and, importantly, I148M has also been implicated 
as an increased risk for fibrosis as a result of steatosis and for HCC 
independently of fibrosis (117, 118). PNPLA3 encodes the protein adiponutrin, 
which is in the same family as ATGL. Given TAG accumulation and subsequent 
NAFLD, I148M has been presented as a loss of function single nucleotide 
polymorphism producing reduced lipolytic activity (119). However, more recently 
Kumari et al. (120) demonstrated no reduction in TAG hydrolysis with adiponutrin 
polymorphism. Instead, their evidence reported increased production of PA and 
subsequent accumulation of TAG in hepatic LDs, akin to the activity of the 
acyltransferases. Moreover, recent lipidomic analysis of the human hepatocyte 
derived cellular carcinoma cell line HUH7 revealed that compared to its wild type 
(WT) counterpart, I148M induced TAG formation from existing unlabeled FAs 
whereas WT PNPLA3 incorporated more TAG from de novo (121). Conversely to 
the Kumari report (122), however, no difference was found in acyltransferase 
activity (121). In addition, WT PNPLA3 was found to enhance remodeling of TAG 
with 18:1, which resulted in a greater ability for hydrolysis, events defective in 
I148M (121). Adding to confusion, each recent report has demonstrated a 
different role for PNPLA3 in the development of NAFLD and HCC with each 
report refuting the findings of the previous study. Collectively, there is a definite 
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association for PNPLA3, but much is left yet to confirm the mechanism whereby 
the single mutation of the gene contributes to these liver diseases. 
 
Oncogenic Lipid Metabolism Cell Signaling 
With greater recognition of lipogenesis in cancer, there has been an increased 
focus on defining the cell signaling mechanisms that lead to cancer initiation. 
Because oncogenesis has been described as a consequence of overnutrition, 
and because DNL activity hinges nutrient status and insulin sensitivity of the 
organism, it should be no surprise that mTORC1 cell signaling cascades play a 
central role in oncogenic lipid metabolism dysregulation. mTORC1 had been 
implicated in adipogenesis by phosphorylating 4E-BP1 leading to its dissociation 
from eukaryotic translation and initiation factor 4E. This process has been shown 
to increase sensitivity to diet induced obesity and promotes IR (122) and is 
mediated by 4E-BP1 induction of peroxisome proliferator-activated receptor 
(PPAR)-γ (123). However, increases in phosphorylated S6K are also noted in 
adipocytes lacking the mTORC1 negative regulator, tuberous sclerosis complex 
I, suggesting a role for S6K in adipogenesis (123). 
The liver produces TAG from de novo sources in the fed state in preparing 
energy reserves during periods of fasting. During the fasting period, ketone 
bodies are produced in the liver as a consequence of acetyl CoA levels 
exceeding the capacity of the TCA cycle (124). However, with IR, ketone body 
production is increased during fed conditions. This can mechanistically be 
explained through mTORC1 signaling cascades as it has been demonstrated 
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that inhibition or tuberous sclerosis complex 1 leads to decreased ketone body 
production by promoting nuclear localization of nuclear receptor co-repressor 1, 
which, in turn increases its inhibitory binding of the major ketone body 
transcription factor PPARα (125); mTROC1 phosphorylation of S6K2 mediates 
these effects on PPARa (126). In addition to inhibition of PPARα activity, a major 
transcription factor for fatty acid oxidation, mTORC1 also promotes lipogenesis 
by suppressing lipolysis via inhibition of adipose triglyceride lipase (ATGL) (127). 
Therefore, it is no surprise recent publications have highlighted the role of mTOR 
in hepatic lipogenesis. 
The first work to identify mTORC1 in hepatic lipogenesis demonstrated that gene 
transcription for DNL was dependent on activation of sterol regulatory binding 
protein 1 (SREBP-1c) and that its activation was dependent on Akt mediated 
activation of mTORC1 (128). Furthermore, the induction of SREBP-1c by 
mTORC1 was inhibited in the presence of rapamycin (128). Successive studies 
employing gene expression profiling identified S6K as the required intermediate 
for SREBP1c activation in vitro (129). Calvisi et al. (130) demonstrate ribosomal 
protein S6 (S6), a target of S6K, is necessary for posttranscriptional SREBP1. 
Supporting this, of more recent work has demonstrated that transcriptional 
regulation of an isoform of SREBP, SREBP1c, is not dependent S6K, while 
posttranscriptional processing is (131). Further explaining SREBP regulation via 
mTORC1, research conducted by Peterson et al. (132) demonstrated that 
mTORC1 phosphorylates and inactivates lipin1. Under basal conditions lipin1, a 
phosphatidic acid phosphatase translocates to the nucleus leading to nuclear 
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eccentricity and thus suppresses transcriptional activity of SREBP1c (132). 
However, mTORC1 phosphorylates lipin1, relegating it to the cytoplasm, which 
induces transcription of SREBP1c and increases target gene mRNA levels (132). 
However, completed works linking mTORC1 to SREBP1c and increased DNL in 
cancer give rise to two important points of emphasis that require further 
elaboration. First, our understanding of the mechanism by which S6K and lipin1 
regulate SREBP1c remains largely unknown. Secondly, while mTORC1 has 
been demonstrated necessary for SREBP activity, recent works have highlighted 
that it is not sufficient to induce activity and requires mTORC2 for sufficient 
phosphorylation of Akt and thus downstream DNL effects (133), especially in 
hepatic tissue (134). SREBP1 activated by mTORC1 and mTORC2 has clearly 
been identified as in important regulator of DNL in hepatic and other cancers and 
has recently been shown to play a predictive role in HCC pathological outcomes 
(135). It should therefore, be no surprise that many targets of DNL, including 
SREBP1 have become targets for cancer therapy. 
Lipid metabolism from de novo sources is an essential metabolic process in 
cancer cell signaling, growth, and proliferation (136) as a downstream 
consequence of increased aerobic glycolysis and anaplerotic input from 
glutamine metabolism. As a result, several studies have examined lipogenic 
enzymes in searching for potential therapeutic susceptibilities in oncogenesis. 
ATP citrate lyase (ACL) links glucose metabolism to FA metabolism by 
converting citrate to acetyl-coA for DNL and other metabolic processes. Inhibition 
of ACL via siRNA has been demonstrated to reduce lipid synthesis and cell cycle 
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progression in an adenoma cell line from glucose, but not acetate (137) 
suggesting the necessity of the enzyme in cancer cell survival via DNL. 
Furthermore, chemical inhibition of ACL was shown to be antineoplastic in vivo 
(137).   
Upon acetyl-CoA generation, ACC carries out the rate-limiting step of DNL by 
carboxylating acetyl-CoA to generate malonyl-CoA. Being the rate-limiting 
enzyme of DNL, ACC has been shown to be markedly upregulated in HCC (138) 
and its knockdown has been shown to induce apoptosis in certain cancers (139). 
Additionally, inhibition of ACC1 by activation of the AMPK pathway has been 
shown to antagonize mTOR activity and deter oncogenic proliferation via 
inhibition of the cyclins, including cyclin D1 (140). However, other cancers growth 
has been enhanced with ACC1 silencing (141), making its target for therapeutic 
intervention controversial. Nevertheless, chemicals such as Soraphen A have 
been used to deter cancer survival by blocking fatty acid elongation (142). 
Independent of malonyl-CoA generation, fatty acid synthase (FASN) primarily 
functions to generate palmitate from malonyl-CoA, but can generate FA directly 
from acetyl-CoA as well; unsurprisingly, it is another enzyme upregulated in 
cancer (143). Its mechanism for overexpression has been hypothesized to be a 
result of increased SREBP1C transcription and/or through reduced proteasomal 
degradation (143). As would be expected, targeted inhibition of SREBP1C 
reduces transcription of FASN, leading to abrogation of neoplastic characteristics 
(144). Furthermore, therapeutic targets of FASN have also been established as 
oncogenic inhibitors (145).   
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The function of FA is dependent upon chain length and saturation; ELOVL and 
SCD carry out these functions respectively and are important in oncogenic risk. 
ELOVL6, one of seven ELOVL isoforms is increased in NASH, a major risk factor 
for HCC development (146). However, other elongases such as ELOVL5 have 
been found to be increased in response to androgen treatment, but were not 
enriched in prostate cancer samples suggesting the isoforms activity may be a 
secondary response to alterations in androgen signaling rather than driving 
oncogenic processes (142). Desaturation post elongation by FASN is carried out 
by SCD; it is also upregulated in numerous cancers (147). 
ACSL has also demonstrated its necessity in maintaining hepatic lipogenesis in 
neoplastic cells by promoting LD formation via FA activation (104). Furthermore, 
overexpression of ACSL4 deterred inflammatory signals in colon 
adenocarcinomas, leading to increased survival (148). Conversely, inhibition of 
ACSL4 has been demonstrated to be effective in reducing breast tumor growth in 
vitro (149) suggesting it may be an effective therapeutic target in cancer. Indeed, 
several drugs such as the thiazolidinediones have successfully inhibited rat 
ACSL4 (150). 
Once synthesized, FAs are trafficked into several cellular processes including 
membrane synthesis, cellular energetics, and storage. FAs incorporated into 
TAG are stored as ER derived organelles, intracellular LD. While several 
signaling pathways induce LD formation the precise mechanism by which they 
are generated is still contended. However, the most generally accepted 
mechanism involves the LD budding from the ER domain. In this theory, neutral 
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lipids accumulate between the bilayer of the ER eventually leading to a lipid 
dense ER bud which, eventually separates from the ER forming a nascent LD 
(151). Healthy tissue including liver contains few small LDs.  However, increased 
numbers of LD’s occurs in NAFLD (109) as well as HCC (108, 152) and other 
cancers (153). To meet hyperplastic and hypertrophic changes in LD’s, many 
physiologic changes must occur including increased lipid production (which is 
met exogenously and, to a greater extent, in cancer from DNL) and reduced 
turnover from lipolysis. With TAG making up the largest component of the LD, it 
would be inferred that activity of ATGL, the rate limiting enzyme of TAG turnover, 
would be reduced. Indeed, studies have demonstrated activation of the mTOR 
pathway blunts lipolysis by hindering the activity of ATGL in adipocytes (154), 
whereas rapamycin treatment leads to reduced LD’s and subsequently 
eicosanoid production (155). In addition, several proteins associated with LD 
structure and accessibility encourage growth and inhibit turnover of oncogenic 
LD’s. 
 
Lipid Droplet Proteins and Hepatic Disease 
Perilipins (Plin) are a family of LD surface proteins. The most well characterized 
LD proteins, their presence is dependent on tissue distribution (156), stage of 
growth (157, 158), and ligand preference (159). Plin2, and Plin3 are the major 
hepatic LD Plin proteins (160). However, perilipin (Plin1) and Plin2 have been 
found to be expressed in development of hepatic steatosis (161, 162) neoplastic 
steatogenesis (163), respectively. Plin1 contributes to TAG sequestration in LD 
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through physical interaction with the protein CGI-58 (164), which is a co-activator 
of ATGL and when bound can increase the lipases activity nearly 20-fold (165), 
whereas KD of CGI-58 has been shown to lead to steatosis and fibrosis through 
a reduction in lipolytic activity (166). Conversely, lipolytic signaling through 
protein kinase A (PKA) leads to dissociation of Plin1 from CGI-58 allowing for 
interaction with ATGL (164). Plin2 has also been suggested to deter lipid 
hydrolysis by excluding ATGL from the LD surface (167). Moreover, obese IR 
rats fed diets rich in conjugated linoleic acid demonstrated significant 
improvements in hepatic steatosis compared to control fed mice in part through 
decrease in Plin2 expression (168). Additionally, genetic ablation of Plin2 
protected mice from diet induced obesity and NAFLD (169). Further supporting 
this role, Plin2 and not Plin3 has been demonstrated necessary for hepatic 
regeneration, in part through its ability to increase lipid content required of 
sustaining hepatic proliferation (160). While Plin3 has not been shown to be 
necessary in regenerating liver, its reduction was shown to improve hepatic 
steatosis while improving murine glucose homeostasis (170). Recent studies 
have further implicated LD proteins in hepatic cancer in demonstrating that 
pharmacologic induction of ER stress in HUH7 cells resulted in an increase of 
several lipid metabolism enzymes and LD proteins including Plin2 (171). This 
finding supports the presence of other LD proteins beyond the Plin family as 
having altered expression in NAFLD/NASH as well as proliferating and neoplastic 
tissue.   
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The Cell death-inducing DNA fragmentation factor 45-like effector (CIDE) is 
another family of proteins that associate with LDs. CIDE proteins function as 
apoptotic proteins (172), but also play an important role in LD maintenance (173). 
Prior to 2003 two human isoforms of CIDE had been identified (CIDE-A and 
CIDE-B), whereas three isoforms existed in mice (CIDE-A, CIDE-B and CIDE-C). 
However, Liang et al. (172) identified CIDE-C, the human homolog to CIDE-C 
and its expression was increased in HEPG2 cell lines compared to adipose 
tissue samples and other cancer cell lines despite lower basal expression in 
hepatic tissue. Controversially, CIDE-C expression has also been demonstrated 
to be reduced in patients diagnosed with HCC and OE induced apoptosis (174). 
However, patient identification does not describe etiology of HCC, warranting 
further investigation as to whether derivation of HCC from HCV or NAFLD 
displays differences in LD protein expression. Recently, Plin1 has been revealed 
to physically interact with CIDE-C, an interaction responsible for LD formation 
through lipid exchange between LD’s (LD fusion) in mature adipocytes (175). 
Additionally, CIDE-A has been shown to share similar function in both brown and 
white adipose tissue (173).   
Where Plin1 deters lipolysis by sequestering the ATGL co-activator CGI-58, 
G0/G1 switch gene-2 (GOS2) also antagonizes ATGL-mediated lipolysis by 
anchoring ATGL to the LD surface, prohibiting hydrolytic activity in adipocytes 
(176, 177) and in hepatocytes (178). The increased TAG content of hepatic LDs 
as a result of GOS2 OE also appears to be important in cancers (179) including 
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hepatic carcinoma as GOS2 was found to have increased expression on 
microarray and RT-PCR screens of patients diagnosed with HCC (180). 
Although oncogenic de novo lipogenesis is well understood, it is only one aspect 
of an elegant system of human metabolism. More interest is still needed in 
teasing apart other aspects of lipid metabolism in oncogenesis. Oncogenic 
signaling directly deters lipolysis through mTOR inhibition of ATGL (154) and 
indirectly impacts lipolysis by increasing LD proteins known to inhibit ATGL (181). 
Conversely, β-adrenergic signaling is known to drive catabolic signaling of lipid 
metabolism, antagonistic to many aspects of mTOR regulated anabolic signaling. 
Stimulation of β-adrenergic receptors is known to increase cyclic AMP levels 
leading to activation of PKA, which triggers lipolysis by stimulating ATGL. 
However, insulin disrupts this signaling cascade (182), the first step in mTOR 
signaling. Interestingly, stimulation of PKA also phosphorylates Plin1 (183), 
causing it to dissociate from CGI-58 (164) and stimulate the rate limiting process 
of lipolysis. Ultimately, the current evidence points to antagonistic roles in β-
adrenergic signaling and mTOR signaling as it pertains to LD protein function 
and location and lipid turnover. However, the mechanisms explaining such 
differences are still very contentious and require further investigation. 
 
Hepatocyte Proliferation 
Cell Cycle 
When placed under stimulatory conditions either in vitro or in vivo, mammalian 
cells begin the process of cell growth and proliferation, often referred to as the 
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cell cycle. Upon initiation by growth factors and other mitogenic stimuli, cells 
must decide to exit a quiescent state, also termed G0, or to actively enter the cell 
cycle. Cells entering the initial phase of the cell cycle, the G1 phase, must 
immediately begin to prepare the cellular environment to undertake the 
momentous effort required for cell replication. Part of this preparation involves 
the accumulation of biomass required for the doubling of other macromolecular 
components necessary for cell proliferation. This initial accumulation of cellular 
constituents is referred to as cell growth, a term often incorrectly applied 
synonymously with proliferation. During the processes entailed in the G1 phase, 
proliferating cells must make critical decisions regarding sustained growth or 
quiescence. Cells completing the growth phase must then pass a critical 
checkpoint, termed the restriction point or “R point,” before transitioning to the 
synthetic or S phase. While several checkpoints exist throughout the process of 
the growth and proliferation, the R point is often considered the rate limiting step 
of the cell cycle because passing this checkpoint ultimately commits the cell to 
completion of the cell cycle (184). During S phase, genomic material is doubled, 
creating two sets of DNA; this process generally requires 6-8 hours for 
completion, however, this process duration varies drastically among cell types 
(185). Prior to cytokinesis mammalian cells, for yet ill-defined reasons, dedicate 
3-5 hours in preparation for entrance into mitosis (the M phase) (185). The M 
phase culminates with the generation of a new daughter cell which can re-enter 
G1 or in the presence of cell cycle inhibitors may revert into a quiescent state (fig. 
1).  
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Figure 1. Visual representation of the cell cycle. 
Upon completion of the M phase or quiescent cells in the G0 phase stimulated by 
mitogens or growth factors, enter the G1 phase of the cell cycle. Near the end of 
the G1 phase, cells reach the restriction or “R” point. Cells bypassing this critical 
checkpoint continue to the S phase and are committed to cell cycle completion. 
Cells not meeting the requirement for continuation are delayed until 
corrections/repairs can be made or continuation is halted completely. Cell then 
double their DNA content during the S phase before entering the G2 phase. The 
subsequent and final M phase or mitosis is where cells halve newly doubled DNA 
content through prophase, metaphase, anaphase, and telophase resulting in two 
complete sets of genetic material and cellular material. Attached to telophase, 
cytokinesis splits the cytoplasm of the cell resulting in a newly formed daughter 
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cells. These cells may then renew the cell cycle or enter G0 until stimulated 
again. 
 
Cell Cycle Proteins 
The cell cycle process is highly regulated, ensuring the integrity and viability of 
rapidly growing and dividing cells. Regulating this process, cyclin family of 
proteins (cyclin’s), cyclin-dependent kinases (CDK’s), and cyclin-dependent 
kinase inhibitors orchestrate the transition between critical points of the cell cycle.  
Cells entering the cell cycle may do so from either renewed entry following 
completion of the M phase or upon stimulation of cells residing in the G0 phase. 
Quiescent cells enter the G1 phase as a consequence of cyclin C forming a 
complex with CDK3 (186). The G1 phase is primarily governed by the activation 
of the D type cyclins and their subsequent binding to CDK 4 or CDK6 (187). Of 
importance, cyclin D1 directs the transition through the R point of the cell cycle. 
In the nucleus of mitogen stimulated hepatocytes, cyclin D1 forms a complex with 
CDK 4-6 downstream of mTOR (188). This newly formed cyclin D1-CDK 4/6 
complex leads to the phosphorylation of tumor suppressor protein Rb, causing it 
to dissociate from E2 factor (E2F) (189). Now dissociated, E2F drives 
transcriptional activation of genes involved in promotion of G1-S transition (190); 
cyclin E is one such gene activated through this process.  
Culminating in the transition past the R point, cyclin D type proteins share an 
inverse relationship with cyclin E. At the initiation of the S phase, cyclin D1 is 
phosphorylated at Thr-286 by Glycogen synthase kinase 3b (GSK3b) (191), 
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flagging it for cytosolic export and subsequent proteasomal degradation (192). 
Once initiated by E2F’s transcriptional activity, cyclin E forms a complex with 
CDK2 (193) completing the transition into, and through much of the S phase. 
Navigation through the S phase is additionally mediated by cyclin A. As with the 
fate of cyclin D1, the S phase triggers the degradation of cyclin E, preventing re-
replication of DNA material (194). This frees CDK2 to reform an activation 
complex with cyclin A, leading to the completion of the S phase (195), while the 
G2 phase is guided by formation of cyclin A-CDK1 complexes (195). The final M 
phase of the cell cycle is initiated by the formation of cyclin B-CDK1 complex and 
its ubiquitination signals termination of the final phase and completion of the cell 
cycle (196). 
 
Cyclin D1 Effects on Metabolism 
Cyclin-CDK complexes play a central role in coordinating expeditious and 
flawless transitions throughout the cell cycle. However, recent work has 
implicated the regulatory governance of cyclin proteins in macronutrient 
metabolism. This is not surprising as protein, carbohydrates, and lipids play 
integral roles in sustaining structural and energetic demands of cell replication. 
Cyclin D1 has been one of the most well defined cyclin proteins in metabolic 
regulation and has been implicated in directing glucose, lipogenesis, and amino 
acid metabolism in the liver.  
In the fasted state, GSK3b leads to cyclin D1 retention in the cytoplasm and its 
subsequent degradation (192). Conversely, in the presence of insulin, Akt 
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phosphorylates and inhibits GSK3b and promotes a significant increase in 
nuclear cyclin D1 (192, 197). This increased presence of cyclin D1 has recently 
been shown to increase transcription of general control non-repressed protein 5, 
which leads to increased acetylation of PGC-1a and repression of 
gluconeogenesis independent of cell cycle progression (198).  
During periods of fasting, amino acid catabolism in part, serves to provide carbon 
intermediates in glucose production. Produced glucose can then be secreted and 
transported to tissues to meet energetic demands. During nutrient sufficiency, 
amino acids serve as anaplerotic substrate as well as building blocks for 
nucleotide synthesis of rapidly dividing cells. Withdrawal of NEAA leads to 
undetectable levels of cyclin D1 and ectopic overexpression of D1 in the same 
conditions rescues proliferative effects (199). Moreover, essential amino acids 
have a more profound effect on cyclin D1 expression than do their non-essential 
counterparts (198), collectively demonstrating the interplay between amino acid 
sufficiency and cyclin D1 in the cellular replication process. 
One of the most profound influences cyclin D1 has demonstrated on metabolism 
is its effects on lipogenesis. Cyclin D1 has been demonstrated to be elevated 
during in NAFLD progression in animals (200) and metformin’s clinical efficacy 
has in part been demonstrated through its inhibition of cyclin D1 (201). However, 
despite its transcriptional and translational activity associated with increased 
steatosis, cyclin D1 has been shown to impede lipogenesis. In the presence of 
glucose, carbohydrate response element binding protein transcriptionally 
regulates hepatic lipogenesis (202–204). Cyclin D1 inhibits lipogenesis through 
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its repression of carbohydrate response element binding protein in a CDK4 
dependent manner (205). However, in addition to its inhibition of lipogenesis, 
cyclin D1 also inhibits PPARα through a CDK4 independent manner (206). Given 
lipolysis regulates PPARα (207), which is well-established for its role in 
promoting fatty acid oxidation (109), these findings establish a unique link 
between cyclin D1, lipid metabolism and hepatocyte proliferation. 
 
Current Objectives 
Cancers are multiform in their etiology and metabolic alterations.  Metabolism is 
a vastly complex system with much cross-talk and feedback mechanisms 
ensuring vitality of the host.  Cancers utilize the foundation of these innate 
designs to ensure their own survival at the expense of the organism.  Many 
challenges exist in curbing such perturbations: multiple enzymatic isoforms, 
different tissue distributions, varying reliance of specific enzymes and proteins 
from cancer to cancer, bridging of macronutrient metabolism and varying roles of 
proteins as anti/pro carcinogenic are but a few obstacles researchers and 
clinicians face in finding therapeutic and lifestyle interventions that successfully 
deter neoplastic survival and oncogenesis respectively.  Alterations in lipid 
metabolism are perhaps the least understood cancer.  Whereas much is known 
about the role of DNL, very little is known about the other arm of lipid 
metabolism: lipolysis.  These unknowns are further compounded when 
considering knowledge in HCC.  Once a disease of underdeveloped nations 
related to HCV, it is now a rapidly growing concern in developed countries as it 
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has strong ties to the existing obesity and diabetes epidemics.  Future 
considerations should be given to such unknowns in oncogenic metabolism such 
as the role of lipolysis and lipid catabolism. The work herein seeks to provide 
address the role ATGL, diet, and lifestyle play in hepatic oncogenesis relevant to 
the etiologies prevalent in Western societies. We utilized both adenovirus and 
siRNA-mediated approaches to manipulate ATGL and cyclin D1 both in-vitro and 
in-vivo systems and employed exercise and caloric restriction protocols with 
varying dietary lipid content during long-term carcinogenesis studies in mice. Our 
studies seek to answer the following questions: Does ATGL-mediated lipolysis 
attenuate hepatic cell proliferation, a risk factor and hallmark of hepatic 
oncogenesis? Do lifestyle factors such as regular endurance exercise or caloric 
restriction influence carcinogen-induced liver cancer? What are potential 
pathways and molecular targets of interest in hepatic oncogenesis relevant to 
developed countries?  
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Obesity is well-documented to promote the development of nonalcoholic fatty 
liver disease including its more advanced stages such as non-alcoholic 
steatohepatitis, cirrhosis and hepatocellular carcinoma. Cyclin D1 (D1) is a cell 
cycle protein that regulates G1/S transition, the rate-limiting step in cell division. 
Thus, D1 is highly expressed in proliferating hepatocytes and liver cancer and its 
overexpression (OE) leads to lipid droplet (LD) accumulation in hepatocytes. 
Conversely, liver-specific knockdown (KD) of adipose triglyceride lipase (ATGL), 
the rate-limiting enzyme in triacylglyceride (TAG) catabolism, promotes LD 
accumulation. To characterize a potential link between D1 and ATGL we 
employed studies in primary hepatocytes and mouse immortalized AML12 cells. 
As expected, in the absence of mitotic stimuli, D1 OE was sufficient to drive DNA 
synthesis in primary hepatocytes. However, these effects are abrogated with the 
OE of ATGL. Knockdown of D1 in the presence of mitogens inhibited DNA 
synthesis and increased ATGL mRNA expression, but KD or chemical inhibition 
of ATGL recovered DNA synthesis. Moreover, cell cycle analysis using flow 
cytometry confirmed that D1 KD increased accumulation of cells in the G0/G1 
phase and reduced cells in the S and G2/M phase; these results were reversed 
with ATGL KD or chemical inhibition. Conclusion: These data illustrate that 
cyclin D1 regulates ATGL to alter hepatic LD metabolism and proliferative 
capacity in primary hepatocytes and AML12 cells.  
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Introduction 
Hepatocytes possess the ability to rapidly proliferate, but remain quiescent under 
normal healthy conditions. However, in response to cellular injuries, such as 
those attributed to chronic liver disease, rapid proliferation of hepatocytes is an 
important event in restoring homeostasis of the liver (208). In addition to injury 
response, hepatocyte proliferation may be stimulated by the presence of growth 
factors and nutrients (209, 210). Identifying the molecular processes that 
contribute to the latter has become increasingly important with the rising 
prevalence of obesity-driven liver pathologies in developed countries, including 
hepatocellular carcinoma (HCC). 
Obesity is an established risk factor for non-alcoholic fatty liver disease (NAFLD). 
Hepatic steatosis, which commonly accompanies obesity and defines NAFLD, 
can lead to a sequela of events known to cause hepatocellular injury and 
increase the risk for HCC development (211). This increased risk is in part, due 
to the induction of molecular mechanisms that initiate hepatocellular proliferation. 
Insulin resistance induced from excessive caloric intake leads to increased 
activation of well-established regulators of oncogenic metabolism such as the 
mechanistic target of rapamycin (mTOR). D1, a downstream target of mTOR 
(188), is a cell cycle protein that, when bound to cyclin dependent kinase 4, 
catalyzes the transition from G1 to S phase of the cell cycle. This transition, 
known as the regulation point or R-point, is an important step in the cell cycle, as 
advancement past this point commits cells to completion of the proliferative 
cycle. D1 is highly expressed in the latter stages of NAFLD progression as well 
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as in HCC (212). In addition to its regulation of a key stage of the cell cycle, D1 
has also regulates glycolytic metabolism (198) and de novo lipogenesis (213), 
known metabolic perturbations in advanced liver disease.  
In the fed state, insulin leads to phosphorylation of several hepatic proteins 
including FOXO1 (214). This suppression of FOXO1 results in suppression of 
gluconeogenesis as well as lipolysis, promoting glycolytic flux and lipogenesis 
(215–217). Additionally, insulin also promotes Akt phosphorylation of PGC-1α, 
leading to inhibition of fatty acid oxidation (218); fatty acid oxidation is also 
inhibited due to insulin’s suppressive effect on FOXO1 (219).  Conversely, during 
periods of increased energetic demand such as those experienced during fasting 
or exercise FoxO proteins promote hepatic TAG catabolism by stimulating the 
expression of adipose TAG lipase (ATGL) (220) and subsequent lipases (221). 
Initially identified in adipose tissue (222), ATGL has subsequently been shown to 
play an important role in other oxidative tissues, including the liver, in promoting 
TAG catabolism. Our lab has shown that ATGL preferentially partitions 
hydrolyzed fatty acids (FAs) towards β-oxidation to meet cellular energetic needs 
(109, 223). Successive studies have further elucidated that in addition to its 
lipolytic action and FA partitioning, ATGL serves as a key signaling node in 
fasting metabolism, leading to PPARα/PGC-1α driven β-oxidation through its 
promotion of the histone deacetylase SIRT1 (224). 
While metabolic derangements have been well-characterized as drivers of 
oncogenesis, little attention has been given to the role of lipid catabolism 
beyond its role in cachexia (225, 226). Importantly, growth factor signaling 
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through the mTOR pathway has been shown to inhibit ATGL (127) while 
catecholamine driven lipolysis represses mTOR signaling in adipocytes (227). 
Moreover, Akt suppression of FOXO1 is necessary for liver regeneration (228), 
collectively suggesting a potential link between ATGL and oncogenic signaling. 
In the present study, we explored the relationship between ATGL and D1, its 
effect on hepatic lipid metabolism, and implications on hepatocellular 
proliferation. Results demonstrate that ATGL is a major regulator of hepatocyte 
proliferation. 
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Materials & Methods 
Animals 
All experimental procedures involving animals were approved by the Institutional 
Animal Care and Use Committee at the University of Minnesota. All experiments 
were conducted in 10-12-week-old C57BL/6J mice or Wistar rats purchased from 
Jackson laboratories (Jackson Laboratory, USA).  All animals were housed under 
constant temperature and humidity under a 12/12 light/dark cycle.  Animals were 
fed standard pellet diet ad libitum with free access to water. 
Surgical Procedures 
All partial hepatectomy (PH) surgeries were performed under isoflurane (Sigma-
Aldrich, St. Louis, MO) anesthesia.  Twenty-four hours prior to PH, animals were 
subjected to tail vein injection of control or ATGL adenovirus to induce liver 
specific OE of ATGL.  Animals were subjected to sham or 2/3 PH as previously 
described.1  Animals were sacrificed at varying time points up to 42-hours post-
surgery. 
Hepatocyte Isolation and Culture 
Mouse and rat primary hepatocytes were isolated by the collagenase perfusion 
method from 10- to 12-week-old animals. Hepatocytes were isolated as we have 
described previously.2  Post isolation, primary hepatocytes were then cultured in 
William’s E media (10% penicillin/streptomycin) with or devoid of insulin (20 
mU/ml) and epidermal growth factor (EGF, 10 ng/ml).  Four hours after plating, 
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fresh media was added and cells were transfected with siRNA or transduced with 
adenovirus targeting cyclin D1, ATGL, and control vectors. Media was 
subsequently replaced every 24 hours during experiments. 
Histology 
A medial section of liver tissue was excised and fixed in 10% buffered formalin 
and subsequently embedded in paraffin blocks. Paraffin-embedded sections 
were prepared for histopathological and immunohistochemical examinations as 
previously described (109).   
Immunofluorescence 
Cells were grown for 72 hours on coverslips. For LD staining, cells were 
incubated with Bodipy™ Deep Red Neutral Lipid Stain (1 μM; Invitrogen) 
overnight at 37°C and subsequently fixed with 4% paraformaldehyde for 30 
minutes and blocked with 1% BSA in media containing or void of EGF and 
insulin. Post fixation, nuclei were stained with DAPI (4′, 6-diamidino-2-
phenylindole) for 10 minutes followed by mounting onto slides for visualization. 
All images were acquired with a Nikon A1 Spectral Confocal Microscope (Nikon 
Ti2000E inverted fluorescence microscope with DIC optics) with a 60X oil 
objective and 0.6 numerical aperture, and prepared using ImageJ (NIH). Images 
from 5 different fields per well were captured and experiments were performed in 
triplicate. 
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Pulse-Chase Studies 
Experiments measuring lipid incorporation (pulse period) to measure TAG 
turnover or FA oxidation were performed in Williams E media (Invitrogen). 
Seventy-two hours after plating, cells were pulsed with 500 μM oleate and trace 
[1-14C] oleate (for turnover) or [1-14C] acetate (for incorporation) for 2 hours. For 
turnover studies, a subset of cells was harvested at the end of the pulse period to 
measure radiolabel incorporation into cellular lipid fractions. Remaining cells 
were washed with PBS and fresh media lacking insulin and serum was added for 
an additional 6 hours (chase period) followed by collection of media and cells for 
lipid extraction. To account for differential rates of incorporation, a serial dilution 
of a TAG standard was prepared and pulse TAG concentrations were normalized 
to this standard. FAs oxidized during the chase period are expressed as a 
percentage of the pulse [14C] TAG. Lipids were extracted and separated into 
different fractions by thin layer chromatography and analyzed as described 
previously (109). For incorporation studies, cells were pulsed with radiolabeled 
acetate and treated as described for pulse conditions. Lipids were extracted and 
analyzed as previously described (109). 
Cell Proliferation  
DNA synthesis was measured using an ELISA BrdU labeling kit (Roche 
Diagnostics, Indianapolis, IN) following manufacturer's protocol. 
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Cell Cycle 
Primary rat hepatocytes and AML12 cells were suspended in PBS. Aggregates of 
cells were gently vortexed to obtain a mono-dispersed cell suspension, with 
minimal cell aggregation. Cells were fixed by transferring this suspension into 
centrifuge tubes containing 4.5 mL of 70% ethanol on ice and kept for 2 hours at 
4°C. Cells were then centrifuged for 5 min at 300xg. Cell pellet was then 
suspended in 1 mL of propidium iodide staining solution at 37°C for 10 minutes. 
The sample was then fed to the flow cytometer and fluorescence of PI bound to 
DNA at 536 nm excitation, and emission at 617 nm was measured.  
mRNA and Protein Analyses 
RT-PCR. Cells were lysed and homogenized in Trizol (Thermo Fisher, Waltham, 
MA). RNA was isolated according to manufacturer’s instructions. Five µg of RNA 
was then subjected to DNAse treatment (Applied Biosystems, Foster City, CA) 
and cDNA synthesis (Applied Biosystems, Foster City, CA) using random 
hexamers. cDNA was subjected to RT-PCR using the LC480 SYBR Green kit 
and the LC 480 Light Cycler (Roche, Indianapolis, IN). Experimental crossing 
points were normalized to Gapdh (mouse) or Rpl32 (rat). The primer sequences 
of gene targets has previously been reported (224).  
Western Blot. Cells or liver tissue were lysed using Lysis Buffer B (0.1% Triton X-
100, 150mM NaCl, 10mM Tris-HCl) and sonicated on ice after incubation on ice 
for 10 minutes. Cell lysates were spun at 21,000 X g for 10 minutes at 4° C. 
Supernatant was collected and protein concentration was determined using the 
BCA method (Thermo Fisher, Waltham, MA). Twenty µg of protein lysate were 
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boiled with SDS sample buffer and subjected to PAGE followed by overnight 
transfer to PVDF membrane (Amersham GE Healthcare). Protein electrophoresis 
was done on poly-acrylamide gels and analyses were performed as described 
previously (224). Anti-Cyclin D1 antibody (Catalog #04-221) was purchased from 
Millipore, (Billerica, MA), anti-CDK1 antibody (Catalog# SC-54) was purchased 
from Santa Cruz (Dallas, TX), anti-ATGL antibody (Catalog# 2183) was 
purchased from Cell Signaling (Boston, MA). All protein was normalized to Actin 
(Catalog# NB600-501) and was purchased from Novus (Littleton, CO). The 
secondary antibody anti-rabbit (Catalog # 7050) conjugated with alkaline 
phosphatase were purchased from Cell Signaling (Boston, MA). 
Statistics 
Results are expressed as mean ± standard error of the mean. Statistical analysis 
was performed using unpaired Student t-test and ANOVA where appropriate. 
Values of P<0.05 were considered statistically significant.  
 
Results 
Cyclin D1 and ATGL serves as a mediators of growth factors on LD 
metabolism and morphology 
To determine if modulating D1 and ATGL impacts LD morphology and turnover 
and any potential connection between the two, we incubated primary 
hepatocytes with siRNA targeting D1 (siD1) and ATGL (siATGL) for 72 hours. 
We conducted knockdown studies in the presence of epidermal growth factor 
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(EGF) and insulin to distinguish between the effects of mitogens and D1 as well 
as ATGL on LD metabolism and morphology. As expected, siATGL led to 
significant increases in the expression of D1, CDK1, and MCM5 and significant 
reductions in carnitine palmitoyltransferase 1α (CPT1α) - a marker of FA 
oxidation (fig. 1A).  As expected, hepatocytes treated with 12C bodipy 
demonstrated significantly increased LD size (fig. 1B).  
In contrast to the effects of siATGL, siD1 led to suppression of early phase cell 
cycle targets including cyclin dependent kinase 1 (CDK1), proliferative marker 
minichromosome maintenance complex component 5 (MCM5), and an increase 
ATGL expression (fig. 1A). Although KD of D1 resulted in significantly more LDs 
per cell, it also reduced LD size, a phenomenon previously described of cells 
experiencing conditions conducive of lipid catabolism (229) (fig. 1B).  
Because of the morphological changes resultant from D1 closely resembled the 
effects expected from lipolysis, despite the presence of growth factors, we next 
determined the effects of D1 KD on hepatocyte TAG metabolism. To do so, we 
conducted a series of pulse-chase experiments using [1-14C] acetate for 
assessment of de novo lipogenesis and [1-14C] oleate to assess TAG turnover 
and oxidation in primary rat hepatocytes treated with siRNA’s targeting D1. 
Knockdown of D1 resulted in a significant reduction in [14C] acetate incorporation 
into hepatocytes (fig. 1C), whereas siD1 resulted in significantly increased TAG 
catabolism and incomplete fatty acid (FA) oxidation (fig. 1 D & E). Interestingly, in 
addition to eliciting opposing effects on LD morphology as well as on proliferative 
and oxidative gene expression, D1 and ATGL knockdown led to significant, 
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reciprocating elevations in gene expression (fig. 1A). Collectively, these data 
suggest D1 and ATGL reciprocally regulate hepatic LD metabolism and 
morphology. 
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Figure. 1. Cyclin D1 knockdown increases LD turnover. 
Primary hepatocytes were isolated from Wistar rats and subsequently treated 
with siRNA targeting cyclin D1 and ATGL. Seventy-two hours after transfection 
cells were harvested for analysis. (A) mRNA expression of proliferative genes 
D1, MCM5, and CDK1 as well as oxidative genes ATGL and CPT1α. (B) 
Inhibition of cyclin D1 lowered [1-14C] acetate incorporation into primary 
hepatocytes. Cells pulsed with [1-14C] oleate had media changed after 6 hours to 
measure (C) TAG turnover and fatty acid oxidation (D). Primary hepatocytes 
were incubated with C12 bodipy to stain for neutral lipids overnight and DAPI for 
nuclei and LD size and number was determined using ImageJ. *P<0.05 
compared to siCTL, #P<0.05 compared to siATGL. 
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Overexpression of D1 alters LD metabolism and morphology independently 
of mitogens 
Because KD of D1 and ATGL in primary rat hepatocytes elicited opposing effects 
on gene expression, LD metabolism, and morphology in the presence of growth 
factors, we next analyzed these effects independent of mitogens through 
overexpression studies using adenoviruses. Where OE of D1 significantly 
increased expression of D1 and CDK1 while repressing ATGL, OE of ATGL 
significantly repressed expression of D1 and CDK1 (fig. 2A & B). [14C] acetate 
incorporation into hepatocellular LDs, a measure of de novo lipogenesis, was 
significantly increased with D1 OE (fig. 2C).  TAG turnover and incomplete 
oxidation of fatty acids were significantly reduced following D1 OE (fig. 2D-E). 
Finally, D1 OE significantly increased both size and number of LD’s independent 
of EGF and insulin, whereas ATGL OE significantly reduced LD size despite 
mitogen stimulation (fig. 1F). Collectively, these data demonstrate D1 alters LD 
metabolism, in opposition to ATGL, in part through the repression of catabolic 
lipid metabolism. 
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Figure. 2. Cyclin D1 overexpression represses ATGL expression 
and LD turnover. 
Primary hepatocytes were isolated from Wistar rats and subsequently treated 
with adenoviruses targeting cyclin D1 and ATGL. Seventy-two hours after 
transfection cells were harvested for analysis. (A & B) mRNA expression of 
proliferative genes targets D1 and CDK1 as well as ATGL. (C) Inhibition of cyclin 
D1 lowered [1-14C] acetate incorporation into primary hepatocytes. Cells pulsed 
with [1-14C] oleate had media changed after 6 hours to measure (D) TAG 
turnover and fatty acid oxidation (E). (F) Primary hepatocytes were incubated 
with C12 bodipy to stain for neutral lipids overnight and DAPI for nuclei and LD 
size and number was determined using ImageJ. *P<0.05 compared to siCTL, 
#P<0.05 compared to siATGL. 
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ATGL attenuates D1 mediated hepatocyte proliferation 
Cyclin D1 is an important mediator of hepatocellular proliferation. Therefore, 
because manipulation of D1 led to opposing effects on ATGL mRNA expression, 
which extended to lipid metabolism, we next sought to determine whether 
metabolic results were recapitulated in hepatocellular proliferation. As expected, 
D1 OE in primary rat hepatocytes cultured in media devoid of EGF and insulin 
was sufficient to increase DNA synthesis (fig. 3A). Alternatively, hepatocytes 
overexpression of ATGL attenuated the effects of EGF and insulin on DNA 
synthesis (fig. 3B). D1 knockdown led to reduced DNA synthesis, but 
simultaneously knocking down ATGL attenuated these effects (fig. 3C). In 
addition to siRNA treatments, primary hepatocytes cultured with the ATGL 
specific inhibitor ASTAT had increased DNA synthesis compared to vehicle 
controls (fig. 3D). To confirm that the alterations in DNA synthesis were due to 
effects on D1, we analyzed primary hepatocytes exposed to siRNA by flow 
cytometry. As expected, D1 KD led to aggregation of cells in the G0/G1 phase 
and a reduction in cells transitioning into the S and G2/M phase (fig. 3E). 
Additionally, ATGL KD led to an increase in cells progressing into the S and 
G2/M phase, while simultaneous D1 and ATGL KD led to a modulation of cell 
cycle progression in between individual siRNA treatments (fig. 3E). Collectively, 
these data support ATGL as a deterrent of hepatocyte proliferation in a D1 
dependent manner. 
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Figure. 3. ATGL and Cyclin D1 differentially regulate proliferation 
in primary hepatocytes. 
Primary hepatocytes were isolated from Wistar rats and subsequently treated 
with adenoviruses targeting cyclin D1 and ATGL. Seventy-two hours after 
transfection cells were harvested for analysis. (A) Cyclin D1 increased 
incorporation of BrdU whereas (B) ATGL inhibits BrdU incorporation despite the 
presence of growth factors. (C) ATGL and cyclin D1 differentially regulate DNA 
synthesis. (D) Cells treated with ATGL specific inhibitor ASTAT show increased 
DNA synthesis both in the presence of growth factors and with D1 knockdown. 
(E) Primary hepatocytes were stained with propidium iodide and analyzed for 
stage of the cell cycle using flow cytometry. *P<0.05 compared to siCTL, #P<0.05 
compared to siD1, †P<0.05 compared to siATGL. 
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Hepatocyte effects on gene expression, LD metabolism, and proliferation 
are recapitulated in AML12 cells 
To recapitulate findings from primary rat hepatocyte experiments, we next 
investigated the effects of ATGL and D1 KD in the immortalized hepatocyte cell 
line AML12. As before, D1 and ATGL knockdowns reciprocally suppressed the 
expression of one another (fig. 4A). Additionally, treatment with siRNA targeting 
D1 alone, or in combination with ATGL, led to a reduction in total lipid area 
quantified from oil red o staining, whereas siATGL led to a significant increase in 
LD area (fig. 4B). Pulse-chase studies confirmed these observations showing 
that siD1 led to an increase in TAG turnover and incomplete oxidation of 
hydrolyzed FAs (fig. 4C & D). DNA synthesis was increased with siATGL, but 
was reduced with siD1 or siD1/ATGL treatments (fig. 4E). Inhibition of ATGL 
activity with ASTAT led to a significant increase in DNA synthesis despite the 
absence of EGF and insulin (fig. 4F). Similar to the data generated in 
hepatocytes, D1 KD increased the number of AML12 cells in the G0/G1 phase 
leading to a reduction of cells progressing through subsequent phases of the cell 
cycle (fig. 4G). Conversely, siATGL led to a significant increase in cells 
progressing to the S phase of the cell cycle and the combined KD of D1 and 
ATGL led to cells fluxing through the cell cycle in between the individual 
treatments (fig. 4G). Collectively, these data demonstrate the antagonistic cross-
talk between ATGL and D1 extends beyond isolated primary hepatocytes. 
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Figure. 4. ATGL and Cyclin D1 differentially regulate proliferation 
in AML12 cells. 
AML12 cells were treated with siRNA targeting cyclin D1 and ATGL or the 
ASTAT and cultured for 72 hours. (A) mRNA expression of D1 and ATGL.  (B) 
Cells stained with oil-red-o had total lipid determined using ImageJ. (C) ATGL 
inhibits BrdU incorporation despite the presence of growth factors. Cells pulsed 
with [1-14C] oleate had media changed after 6 hours to measure TAG turnover 
(C) and fatty acid oxidation (D). DNA synthesis measured using BrdU 
incorporation in cells treated with siRNA (E) and ASTAT (F). (G) AML12 cells 
were stained with propidium iodide and analyzed for stage of the cell cycle using 
flow cytometry. *P<0.05 compared to siCTL, #P<0.05 compared to siD1, †P<0.05 
compared to siATGL. 
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ATGL OE limits liver regeneration 
To investigate the role of ATGL and D1 in an in vivo system, we performed a 70 
percent partial hepatectomy, which is a common model for investigating liver 
regeneration and proliferation (230). Liver tissue harvested 42 hours post HR 
exhibited a significant reduction in staining of the proliferative marker Ki-67 and a 
marked reduction in steatosis in response to ATGL OE (fig. 5A). Western blots 
demonstrated a significant increase in D1 and CDK1 with GFP treatment 
compared to sham surgery animals, whereas ATGL OE reduced these markers 
compared (fig. 5B). This data collectively points to an antagonistic cross-talk 
between ATGL and D1, which results in alterations in LD biology, lipid 
metabolism, and reductions in hepatocellular proliferation in an in vivo model. 
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Figure. 5. ATGL inhibits hepatocyte regeneration after partial 
hepatectomy. 
Forty-two hours after completion of 70 percent partial hepatectomy, animals were 
sacrificed and liver tissue was analyzed for lipid accumulation (A) and the 
proliferative marker Ki-67 (B). Western blot of hepatic tissue demonstrated mice 
treated with ATGL adenovirus had reduced expression of cyclin D1 and CDK1 
protein compared to GFP control and sham surgery treated animals. (C) 
Infographic of summary of findings. 
 
 
 
 
 
 
 
 
64 
Discussion 
Alterations in energy metabolism resulting from overconsumption of calories are 
well known to increase the risk of obesity and NAFLD. Once thought of as inert 
organelles, LD’s are now widely considered to play a dynamic role in a wide 
range of cellular processes.  Accumulation of LD, the hallmark of NAFLD, has 
attracted much attention in attempting to explain the biology of this metabolic 
state and its links to a spectrum of diseases.  
The accumulation of hepatic LDs can result from either an increase in synthesis 
(de novo lipogenesis or fatty acid uptake) or a suppression of turnover (lipolysis). 
Indeed, both mechanisms have demonstrated relevance as it pertains to the 
development of steatosis (109, 160, 221, 231). In the fed state, the liver 
increases TAG synthesis due to increased glucose catabolism. This is in part 
explained by nutrients and growth factors well-documented effects on cell 
signaling pathways promoting lipogenesis. One key signaling node, mTOR, has 
been shown to activate cyclin D1 in response to such stimuli (232). Importantly, 
D1 expression has been shown to influence both glucose metabolism and lipid 
synthesis (198, 213, 233). In the present study, D1 was both shown to be a 
mediator of growth factors (fig. 1) and sufficient in the absence of growth factors 
(fig. 2) to drive hepatocellular LD accumulation and cell proliferation.   
Lipolysis, which is initiated during periods of fasting or exercise, provides fatty 
acids for oxidation to meet cellular energy needs. Our laboratory has previously 
demonstrated that hepatic ATGL expression is sufficient and necessary in 
preventing and reversing steatosis (109). Additionally, growth factors suppress 
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ATGL-driven lipolysis (127) and lipolysis has been shown to antagonize mTOR 
(227) in adipocytes, suggesting a possible extension of these effects in the liver. 
Indeed, data from this study recapitulates previous findings demonstrating ATGL 
as a key enzyme in LD catabolism and identify cross-talk relationship with D1 
that determines hepatocellular TAG turnover, FA oxidation, and LD size and 
number. 
Paradoxically, accumulation of lipid leading to steatosis can further lead to 
subsequent pathologies, yet accumulation of LD is necessary for proliferating 
cells (160). In the liver, the loss of LD associated protein perilipin 2 is sufficient to 
ameliorate steatosis and reduce D1 expression, leading to a delay in liver 
regeneration (160). This is relevant to the current study since perilipin 2 is highly 
expressed in fatty livers (234) and is known to antagonize lipolysis (235). D1 is 
also widely recognized as a key signaling node in hepatocellular proliferation 
(188). Supporting this work, the results here show that in addition to effects on 
LD morphology and metabolism, D1 promoted DNA synthesis even in the 
absence of growth factor stimulus. The data also show for the first time that 
ATGL expression can antagonize the effects of growth factors in driving cell 
proliferation and rescue the stimulatory effects of D1. Furthermore, results from 
experiments inhibiting lipolysis with ASTAT indicate that the activity of ATGL and 
not merely its expression play an important role in mitigating the effects of D1 on 
LD metabolism and hepatocyte proliferation. Finally, results from the present 
study reveal that ATGL’s inhibitory effects on proliferation of hepatocytes and 
immortalized liver cells are carried out in a D1 dependent manner, limiting 
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transition from the G1 into the S phase; importantly, the inhibitory effects of 
ATGL on proliferation were recapitulated in an in vivo model suggesting 
translational applications. 
In conclusion, data from this work shows for the first time that cyclin D1 increases 
lipid accumulation in hepatocytes and mouse livers, in part, through its 
suppression of ATGL catalyzed lipolysis. Furthermore, the work also points to a 
cross-talk relationship between the two targets and further suggests ATGL 
activity is sufficient and necessary in limiting both metabolic and proliferative 
derangements associated with obesity and risk for subsequent pathologies. 
Future work will need to focus on identifying the mechanism explaining these 
results, which will provide further insight into metabolic and pathologic features of 
obesity related diseases, potentially opening the door for translational 
investigations in human populations. 
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Caloric restriction (CR) and endurance exercise elicit wide-ranging health 
benefits including reduced risk of select cancers. In addition, diet composition 
influences oncogenesis, although its interactions with exercise and CR are not 
well understood. Therefore, to investigate the potential interactions between diet 
and lifestyle interventions on liver tumorigenesis, the carcinogen 
diethylnitrosamine (DEN) was administered to 72 male C57Bl/6 mice that were 
subsequently fed diets enriched with lard (CTL) or olive oil (OO) and were 
further stratified to voluntary wheel running (Ex) or 30% CR for 49 weeks. While 
Ex and diet composition did not influence liver oncogenesis, CR prevented 
hepatic tumor formation. Additionally, CR reduced steatosis, hepatocyte 
ballooning, inflammation and immune cell infiltration, all of which are hallmarks 
in the progression of non-alcoholic fatty liver disease (NAFLD) to liver 
tumorigenesis. RNA sequencing of non-transformed liver tissues revealed 
changes in metabolic pathways and reduced inflammation, cytokine production, 
stellate cell activation and migration, and genes associated with liver injury and 
oncogenesis. These data demonstrate that CR protects against steatosis, liver 
inflammation, and liver injury and is a robust deterrent of carcinogen-induced 
hepatic oncogenesis. 
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Introduction 
Alterations in energy metabolism resulting from overconsumption of calories are 
well known to increase the risk of obesity, which accounts for nearly 20% of all 
cancers in the U.S. (27). In addition, prospective epidemiological studies have 
shown that obesity increases the risk of mortality from nearly every major form of 
cancer including liver cancer (29). The mortality rate for NAFLD-derived 
hepatocellular carcinoma (HCC), the most common liver cancer, is higher than 
other etiologic factors such as hepatitis viral infection with mortality rates as high 
as 61% within 1 year of diagnosis (236). While epidemiologic studies have linked 
obesity to increased cancer risk and mortality, the molecular mechanisms 
underlying this relationship have not been fully elucidated.  
Adherence to the Mediterranean Diet (MD), considered the gold-standard for 
diets, is associated with a lower incidence of cancer and has been shown to 
reverse the effects of NAFLD in humans (237). OO, which is rich in 
monounsaturated fatty acids (MUFAs), is a food regularly consumed by 
adherents of the MD has been reported to provide numerous health benefits 
(238). Studies in mice and humans have shown consumption of high MUFA 
containing oils, such as olive oil, to be protective against NAFLD development, 
even with diets high in fat content (239). 
Sedentary lifestyles are well-established contributors to obesity, metabolic 
disease, and tumorigenesis (27). Exercise on the other hand, has been shown to 
reduce mortality and protecting against numerous lethal disease such as cancer 
(240). Of the two major forms of exercise, endurance and resistance, the former 
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has proven more beneficial to cardiovascular health (241) and obesity (242). 
Endurance exercise is also an effective therapeutic tool in reversing NAFLD, a 
major risk factor for liver tumorigenesis (243). Given these benefits, it is perhaps 
not surprising that numerous studies have demonstrated endurance exercise to 
be protective against liver tumorigenesis (244). Importantly, physical activity by 
adherents of the MD lowers the risk of morbidity and mortality more than their 
inactive counterparts (245) suggesting a cooperative role between the MD and 
lifestyle interventions. 
Unlike increased morbidity and mortality associated with sedentary lifestyles, CR 
has a long-standing history of extending disease free longevity (246). CR has 
also been shown to prevent or delay mammary (247), prostate (248), brain (249), 
intestinal (250), and pancreatic cancers (251). Yet, despite CR proven 
effectiveness as a therapy in reversing and preventing NAFLD (252), no hepatic 
CR oncogenesis studies have investigated exposures and pathologies relevant 
to Western societies, such as through NAFLD. Additionally, while CR and 
exercise lower the risk for numerous cancers, the molecular pathways involved in 
elucidating these effects are not fully understood. Therefore, to investigate any 
collaborative link between dietary fat composition, akin to a Western versus a 
Mediterranean diet, and either regular aerobic exercise or CR, a long-term liver 
carcinogenesis study using DEN was employed. Results show dietary 
composition and exercise had no effect on tumor development, but CR reduced 
liver inflammation and injury and abrogated tumorigenesis.  
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Materials & Methods 
Animals and Chemicals 
Four-week-old male C57BL/6 mice were purchased from Charles River 
Laboratories (Wilmington, MA, USA). All mice were maintained at the University 
of Minnesota Animal Facilities in accordance with the Institutional Animal Care 
Guidelines and all experimental procedures were approved by the Institutional 
Animal Care and Use Committee at the University of Minnesota. Mice were 
individually housed under a 12:12 light/dark cycle with free access to water. DEN 
and glyceryl triochtonoate were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). The final injection mixture was prepared by suspending DEN in glyceryl 
triochtonoate to a concentration of 2.5 mg/ml just prior to injection. At 4 weeks of 
age, all mice were given a single intraperitoneal injection of DEN mixture (25 
mg/kg body weight) to induce liver tumorigenesis.  Upon injection, mice were 
individually housed in cages containing 1/8” irradiated corncob bedding for the 
duration of the study. A subset of mice (n=20) were housed in modified cages 
containing a running wheel, which was retrofitted with a bicycle computer to track 
weekly distance (Km) and wheel revolutions as a means of tracking activity 
levels. To achieve CR, daily food consumption was determined by weighing lard 
and OO diet intakes on consecutive days weekly. Daily aliquots of CR CTL and 
OO diets were prepared by weighing 70% of the average daily food weight 
consumed by sedentary (Sed) animals; aliquots were prepared weekly and 
stored at 4°C. Food consumption and body weight were measured weekly. Forty-
nine weeks after injection, animals were sacrificed for tissue and serum collection 
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after a 4 hour fast. After anesthesia, livers were harvested by surgical resection 
and surface nodules were counted.   
Diets 
To examine differences between dietary fat typically consumed by Western and 
Mediterranean inhabitants regarding tumorigenesis, Sed (n=32) and Ex mice 
(n=20) were fed purified diets (AIN-93G) purchased from Harlan Teklad 
(Indianapolis, IN, USA). Sed and Ex mice were stratified to receive diets where 
25% of the kcal were derived from fat (15% of Kcal of fat was derived from either 
lard (TD.150656) or olive oil (TD.150657) and soybean oil contributed the 
remaining 10%) (Table S1). CTL CR or OO CR diets (TD150658 and TD.150659 
respectively) were made to contain 30% less macronutrient content compared to 
ad libitum diets (10/10/10 CHO/FAT/PRO). CR diets were then supplemented 
with added vitamin and mineral mix (AIN-93G-MX and AIN93-VX respectively) to 
ensure animals remained nutrient sufficient. If initiated at a young age, CR has 
been shown to have deleterious developmental effects (253). Therefore, we 
gradually restricted CR mouse food in 10% increments over three weeks 
beginning at 5 weeks of age until a 30% reduction was achieved (Fig. S1A).  
NAFLD & NASH Scoring 
Hepatocellular steatosis, inflammation, Mallory body and Kupffer cell infiltration, 
and ballooning were scored by a pathologist (J.C.M.) (VA Medical Center, St. 
Paul, MN) blinded to all treatment groupings. 
 
Immunohistochemistry and Histological Analysis 
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A medial section of liver tissue was excised and fixed in 10% buffered formalin 
and subsequently embedded in paraffin blocks or placed in optimal cutting media 
and slowly frozen in liquid nitrogen before paraffin embedding.  Paraffin-
embedded sections were prepared for histopathological and 
immunohistochemical examinations as previously described (109). Cryo blocks 
were stored at -80°C until preparation. Cryosections of hepatic tissue were 
stained with Oil-Red-O as previously described (109) and analyzed using ImageJ 
to determine lipid area per field of 5 randomly selected views per animal from 
respective treatment groups.  
 
RNA extraction, library preparation, and next-generation sequencing 
Six samples of non-transformed, snap frozen hepatic tissue were randomly 
selected using a random number generator from the CTL Sed and CTL CR 
groups for RNA-sequencing. RNA was extracted from snap frozen liver tissue 
using the RNEasy RNA mini kit purchased from Qiagen (Valencia, CA, USA). A 
total of 12 RNA samples [6 samples per group x 2 groups (CTL & CR)] were sent 
to University of Minnesota Genomics Core (UMNGC) for quality check, library 
preparation, and sequencing. Eukaryotic RNA isolates were quantified using a 
fluorimetric RiboGreen assay and total RNA integrity was assessed using 
capillary electrophoresis (e.g., Agilent BioAnalyzer 2100). Only samples higher 
than 1 microgram with a RIN of 8 or greater proceeded to sequencing. Total RNA 
samples were converted to Illumina sequencing libraries using Illumina’s Truseq 
RNA Sample Preparation Kit (Cat. # RS-122-2001 or RS-122-2002) or stranded 
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mRNA Sample Preparation kit (Cat. # RS-122-2101). One microgram of total 
RNA was oligo-dT purified using oligo-dT coated magnetic beads, fragmented 
and then reverse transcribed into cDNA. The cDNA was fragmented, blunt-
ended, and ligated to indexed (barcoded) adaptors and amplified using 15 cycles 
of PCR. Final library size distribution was validated using capillary 
electrophoresis and quantified using fluorimetry (PicoGreen) and via Q-PCR. 
Indexed libraries were then normalized, pooled and size selected to 320bp +/- 
5% using Caliper’s XT instrument. Truseq libraries were hybridized to a single 
read flow cell and individual fragments were clonally amplified by bridge 
amplification on the Illumina cBot. Once complete, the flow cell was loaded on 
the HiSeq 2500 and sequenced. Upon completion of read 1, an 8bp forward and 
8bp reverse (i7 and i5) index read was performed. Base call files for each cycle 
of sequencing were generated by Illumina Real Time Analysis (RTA) software. 
Primary analysis and de-multiplexing were performed using Illumina’s bcl2fatstq 
software version 2.17.1.14.  
For the RNA sequencing analysis, 50bp FastQ Reads (n=12 Million per sample) 
were trimmed using Trimmomatic (v 0.33) enabled with the optional “-q” option; 
3bp sliding-window trimming from 3’ end requiring minimum Q30. Quality control 
checks on raw sequence data for each sample were performed with 
FastQC. Read mapping was performed via Bowtie (v2.2.4.0) using the UCSC 
mouse genome (mm10) as reference. Gene quantification was done via 
Cuffquant for FPKM values and Feature Counts for raw read counts. 
Differentially expressed genes were identified using the edgeR (negative 
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bionomial) feature in CLCGWB (Qiagen, Valencia, CA) using raw read counts. 
The generated list was filtered based on a minimum 2X Abs Fold Change and 
Bonferroni corrected p < 0.05. These filtered genes were then imported to 
Ingenuity Pathway Analysis Software (Qiagen, Valencia, CA) for pathway 
identification. 
Ingenuity Pathway Analysis (IPA) 
Isoforms that exhibited a log2 fold change greater than 1 and a false detection 
rate (FDR) less than 0.05 were subjected to Ingenuity Pathway Analysis (IPA 4.0, 
Ingenuity Systems, www.Ingenuity.com). The input isoforms were mapped to 
IPA’s knowledge bases, and the relevant biological functions, networks, and 
pathways related to the treatment were identified. 
Reactive Oxygen Species 
Reactive oxygen species were detected from 50µg of non-transformed hepatic 
tissue homogenate using the OxiSelectTM in-vitro reactive oxygen species kit 
(Cell Biolabs, San Diego, CA) per manufacturer’s instructions.  
Serum Analyses 
Serum was isolated from whole blood samples taken via cardiac puncture at the 
time of animal sacrifice and kept on ice until centrifugation. Samples were spun 
at 5,000 X g for 10 minutes and supernatant was aliquoted and stored at -80°C. 
Non-esterified fatty acids (NEFA) and total ketone bodies were analyzed using 
the free fatty acid and total ketone body kits respectively purchased from Stanbio 
labs (Boerne TX, USA).  Total ketone bodies and serum insulin were analyzed 
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using the total ketone body isolation and insulin kits respectively purchased from 
Wako (Richmond, VA). 
Statistical Analysis 
Statistical analysis was performed using Graphpad Prism7. Data are expressed 
as mean ± SEM. Statistical analyses were performed using Student t test or 
ANOVA where appropriate. Statistical analysis for RNA-seq is described in detail 
under the respective methods. Differences were considered significant at P < 
0.05. 
Gene Sequencing Data deposition 
RNA-seq data have been uploaded to the NCBI Sequencing Read Archive, 
www.ncbi.nlm.nigh.gov/sra (accession no. SRP103046). This article contains 
supporting information online at 
www.ncbi.nlm.nih.gov/Traces/study/?acc=SRP103046. 
 
Results 
Phenotypic effects of diet, Ex and CR 
To determine the independent and potentially synergistic effects of exercise, CR, 
and diet lipid composition on liver cancer, 4-week-old male C57BL/6 mice were 
given a single intraperitoneal of DEN. Subsequently, mice were stratified to 
receive diets with fat content being enriched in either lard or OO (Table S1). Mice 
were further subcategorized to either remain Sed or given unlimited access to 
running wheels or incremental CR (Fig. S1A). Sed and Ex mice were fed ad 
libitum whereas CR mice were fed 70% of calories of their respective Sed CTLs. 
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Mice with access to running wheels ran over 45 Km during the first week of 
exposure, but running wheel use gradually declined especially during the first 6 
months (Fig. 1A-B; Fig. S1B). Within the Ex groups, mice fed the OO diet ran 
significantly more than those fed the CTL diet over the duration of the study (Fig. 
1B). However, like total running wheel use, the increased running of mice fed the 
OO diet was only evident during the first 6 months of the study (Fig. S1B). OO 
significantly reduced food intake in Sed mice, but not in those in the Ex group 
(Fig. 1C-D). As expected, CR reduced body weight gain, which was unaffected 
by dietary lipid composition (Fig. 1E & F). Consistent with reduced body weight, 
both CR groups had smaller inguinal fat pads (Fig. S1C) although the reduction 
in epididymal fat pads was only observed in the CR OO mice (Fig. S1D). Over 
the course of the study, both Ex groups gained more body weight than their Sed 
CTLs (Fig. 1F) perhaps due to increased muscle mass, which commonly occurs 
with exercise training (254). There were not treatment effects on food efficiency 
defined as body weight gain/food intake (Fig. S1E).   
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Supplementary Table 1. Description of components (g/Kg) and macronutrient 
content (% kcal) of diets. 
 CTL 
(TD.150656) 
OO 
(TD.150657) 
CR CTL 
(TD.150658) 
CR OO 
(TD.150659) 
 Sed and Ex mice CR mice 
Components g/Kg 
Casein 200.0 200.0 196.0 196.0 
L-Cystine 3.0 3.0 2.94 2.94 
Corn Starch 359.186 359.186 349.98 349.98 
Maltodextrin 132.0 132.0 129.2 129.2 
Sucrose 100.0 100.0 98.0 98.0 
Lard 65.0 ----- 64.2 ----- 
Olive Oil ----- 65.0 ----- 64.2 
Soybean Oil 43.2 43.2 42.7 42.7 
Cellulose 50.0 50.0 49 49 
Mineral Mix, AN-93G-
MX 35.0 35.0 50 50 
Vitamin Mix, AN-93-
VX 10.0 10.0 14.29 14.29 
Choline Bitartrate 2.5 2.5 3.57 3.57 
TBHQ, antioxidant 0.014 0.014 0.02 0.02 
 
% kcal 
Protein 17.9 17.9 17.7 17.7 
Carbohydrate 57.1 57.1 57.3 57.3 
Fat 25 25 25 25 
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Figure 1. Phenotypic responses to treatment regiments. (A) 
Average weekly running distance for each month of the study and (B) collective 
average running distance of OO and CTL fed mice. (C) Average daily food intake 
by month and (D) average daily food consumption over the course of the study. 
(E) Monthly body weight change and (F) average total body weight change. Data 
are presented as ± SEM. *P<0.05 compared to CTL, #P<0.05 compared to Sed. 
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Supplemental Figure 1. Phenotypic and metabolic parameters 
are influenced by Ex and CR. (A) Schema of the study protocol. Four-
week-old C57BL/6 mice were given an intraperitoneal injection of DEN at 25 
mg/kg body weight. Mice were subsequently randomly stratified into two dietary 
groups (CTL or OO) and then again into one of three groups: Sed, Ex and CR. 
To preserve normal development, 30% macronutrient restriction was achieved 
stepwise over the course of 3 weeks; all mice were individually housed. (B) 
Weekly distance parceled into 6 month increments.  (C & D) Epididymal and 
inguinal fat pad weights. (E) Food efficiency analysis. (F) Serum ketone body 
concentrations analyzed from CTL and CR mice. (G) Non-esterified fatty acids 
(NEFA) analyzed in serum from CTL and CR mice. (H) Serum insulin analysis of 
CTL and CR mice. Data are presented as ± SEM. *P<0.05 compared to CTL, 
#P<0.05 compared to Sed. 
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Caloric Restriction Prevents Hepatic Tumorigenesis 
Upon termination of the study, 49 weeks after DEN administration, liver surface 
nodules were quantified. Tumors were present in approximately half of mice in 
the Sed and Ex groups irrespective of diet (Fig. 2A). However, no surface 
nodules were observed in any mice in the CR groups. Clinical diagnosis of 
tumors was confirmed by a blinded pathologist from H&E stained slides and 
demonstrated a diversity of hepatic tumors including hepatocellular carcinomas, 
hepatoblastomas, adenomas, and cholangiocarcinomas. Pearson’s correlation 
analysis demonstrated a significant positive correlation between body weight 
change or food intake and tumor number (Fig. 2B-C), while activity level was not 
correlated to surface nodules (Fig. 2D).  
Because no differences in tumor formation were observed between dietary or 
exercise interventions, subsequent analyses were largely focused on the 
differences between Sed and CR groups fed the CTL diet. Consistent with 
resistance to tumor formation, non-transformed livers of CR mice showed an 
~85% reduction in staining of the proliferative marker Ki-67 (Fig. 2E). Collectively, 
this data demonstrates CR robustly protects mice from hepatic tumorigenesis 
initiated by DEN and promoted through ad libitum caloric intake.
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Figure 2. CR prevents hepatic tumor formation. (A) Scatter plot of 
quantified visible surface nodules per mouse and representative images of livers 
from mice from each group; horizontal bars represent group mean. (B-D) 
Pearson’s correlation analysis of average food intake, average fold body weight 
change, and average weekly running wheel activity with surface nodule count. 
(E) Representative 10X and 40X images from 5 randomly selected views per 
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animal from non-transformed tissue of CTL and CR mice and quantification of 
positively stained nuclei. Data are presented as ± SEM. *P<0.05 compared to 
CTL, #P<0.05 compared to Sed. 
 
Caloric Restriction Prevents Pathologies Associated with NAFLD-Driven 
Liver Cancer 
A recent model describing the progression of NAFLD to liver cancer suggests 
that steatosis, inflammation and cellular damage may act simultaneously rather 
than in succession in the development of liver cancer (255). In this context, CR 
has been shown to improve hepatic lipid metabolism and reduce hepatic 
inflammation (256). Indeed, compared to their dietary CTL, liver weights were 
significantly lower in CR mice, but higher in the Ex mice (Fig. 3A). The OO diet 
increased liver weights within the Ex group, but lowered them in response to CR 
(Fig. 3A). Livers from CR mice showed reduced lipid droplet accumulation as 
visualized with H&E staining, which was confirmed with Oil Red O staining (Fig. 
3B & C).  These data were further confirmed via steatosis scoring of H&E slides 
performed by a blinded pathologist (Fig. 3D) demonstrating that CR prevented 
steatotic burden. In addition, serum ketone body concentrations were 
significantly increased in CR mice (Fig. S1F) in the absence of changed serum 
non-esterified fatty acids (Fig. S1G) and reduced insulin (Fig. S1H), suggesting 
reduced steatosis in these mice is partially explained by increased oxidation of 
fatty acids. Pearson’s correlation analysis showed a strong positive relationship 
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between steatosis with tumor burden (Fig. 3E) supporting the established link 
between NAFLD and hepatic tumorigenesis (257–259).  
In addition to abrogating steatotic burden, CR also reduced markers of immune 
cell infiltration.  Staining of neutrophils (Fig. 4A) and CD3 T-cells (Fig. 4B) and 
the presence of Kupffer cells (Fig. S2A) was reduced in livers of CR mice. 
Consistent with reduced immune cells, CR significantly attenuated lobular 
inflammation (Fig. 4C), hepatocyte ballooning (Fig. 4E) and the presence of 
Mallory bodies (Fig. S2B). The pathological scores associated with lobular 
inflammation and ballooning, but not Mallory bodies, correlated with tumor 
burden (Fig. 4D and F and Fig. S2C). Despite the frequent association of 
inflammation with ROS, there were no differences in hydrogen peroxide or total 
reactive oxygen species in liver tissues of CR mice (Fig. S2D). Collectively, this 
data show that CR reduces hepatic steatosis, inflammation, cellular damage, and 
immune cell infiltration, markers associated with NAFLD progression that 
correlate to hepatic tumorigenesis.  
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Supplemental Figure 2. CR modulates additional markers of 
hepatic inflammation and immune cell infiltration.  
(A) H&E images revealed differences in Kupffer cell presence in CTL and CR 
mice. (B) Mallory bodies from H&E staining of representative 40X images from 5 
randomly selected views per animal and blinded pathologist scoring of lobular 
inflammation. (C) Pearson’s correlation of Mallory bodies. (D) Quantification of 
Hydrogen Peroxide and other non-hydrogen peroxide free radicals (DCF) found 
in non-transformed tissue from CTL and CR mice. 
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Figure 3. CR prevents hepatic steatosis.  
Liver weight to body weight ratio (A) of mice (n=57) and representative H&E 
images (B) of livers from CTL and CR mice. (C) Oil Red O staining and 
quantification from representative 10X and 40X images from 5 randomly selected 
views per animal from non-transformed tissue of CTL and CR mice and 
quantification of average lipid stained area per field. (D) Steatosis scoring 
assigned to each representative case as performed by a pathologist (J.C.M.) 
blinded to treatments; horizontal bars represent group means (E) Pearson’s 
correlation of steatosis score with surface nodules. For E; larger data points 
represent multiple mice falling with the same nodule/score intersection.  Data are 
presented as ± SEM. *P<0.05 compared to CTL, #P<0.05 compared to Sed.
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Figure 4. Caloric restriction abrogates pathologies associated 
with NAFLD progression.  
(A) Immunohistochemical staining of neutrophils from representative 40X images 
from 5 randomly selected views per animal from non-transformed tissue of CTL 
and CR mice and quantification of positively stained nuclei. (B) 
Immunohistochemical staining of CD3+ T-cells from representative 40X images 
from 5 randomly selected views per animal from non-transformed tissue of CTL 
and CR mice and quantification of positively stained nuclei. (C) Lobular 
inflammation from H&E staining of representative 40X images from 5 randomly 
selected views per animal and blinded pathologist scoring of lobular 
inflammation. (D) Pearson’s correlation of lobular inflammation to surface 
nodules. (E) Hepatocellular ballooning from H&E staining of representative 40X 
images from 5 randomly selected views per animal and blinded pathologist 
scoring of lobular inflammation. (F) Pearson’s correlation of ballooning to surface 
nodules. For D-E; larger data points represent multiple mice falling with the same 
nodule/score intersection. Data are presented as ± SEM. *P<0.05 compared to 
CTL, #P<0.05 compared to Sed CTL. 
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Non-Transformed Liver Tissue from CR and CTL Mice Produce 
Significantly Distinct Gene Profiles 
Because CR mice developed no visible tumors, transcriptome profiling of non-
transformed tissue was performed to elucidate potential mechanisms underlying 
the carcinogenic process in our model. Initial analysis demonstrated a total of 
487 differentially expressed genes (Fig. S3A) with the top 20 up/downregulated 
genes listed in (Fig. 5A). To better understand the biological relevance of the 
observed differences in the gene signature profiles of CR and CTL mice, multiple 
parameters were analyzed using Ingenuity Pathway Analysis (IPA). IPA’s initial 
assessment identified a total of 223 canonical pathways as being significantly 
changed between CR and CTL groups. Interestingly, of the10 most significantly 
impacted pathways, 9 were related to hepatic inflammation, immune cell 
activation, and hepatic fibrosis (Table 1); these data corroborated the histological 
analyses (Fig. 4). Further investigation of the identified pathways elucidated cell 
adhesion/movement (Fig. 5B), toll-like receptor signaling (Fig. S4A), 
lipid/carbohydrate metabolism (Fig. S4B), and cell growth and proliferation (Fig. 
S4B) as regulatory networks relevant to transcriptomic alterations. From this 
information, IPA predicted suppression of several features relevant in the NAFLD 
progression to liver cancer including hepatic stellate cell activation and 
proliferation (Fig. 5C) and HCC (Fig. 5D). 
Because gene signatures, canonical pathways, and downstream 
networks/signaling pathways corroborated previous data linking NAFLD and 
subsequent pathologies such as inflammation and cellular damage leading to 
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non-alcoholic steatohepatitis (NASH), IPA was used to elucidate downstream 
effects of pathway and network influences. Initial analysis identified 188 biologic 
functions, diseases, and toxological outcomes related to our identified 
differentially expressed gene profiles. The most significant diseases and 
biological functions were categorized by steatosis, liver damage, liver necrosis, 
hepatocellular adhesion and fibrosis, hepatic hypertrophy and hyperplasia, and 
liver cancer; CR robustly altered gene profiles attenuating these pathologies in 
comparison to CTL mice (Table 2). Importantly, these gene signatures matched 
the biochemical and histological profiles previously identified (Fig. 4 and 5). 
Collectively, these results suggest CR leads to unique transcriptomic alterations, 
which are relevant to numerous canonical pathways and gene networks 
associated with NAFLD progression to liver cancer.  
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Figure 5. Caloric restriction produce significantly distinct gene 
profiles from control mice.  
(A) Heat map of the top 10 most upregulated and 10 most downregulated genes. 
(B) Cell adhesion/migration pathway was identified as a major signaling pathway 
by IPA. (C) IPA identification of hepatic stellate cell activation and hepatic stellate 
cell proliferation as top biological functions. (D) IPA identification of 
hepatocellular carcinoma as the most significant disease associated with gene 
signatures. For (B-D) Green targets indicate lower expression in CR compared to 
CTL and red indicate increased expression; table in (B) corresponds to (B-D). 
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Supplemental Figure 3. CR causes divergence of genes in 
comparison to CTL mice.  
(A) Volcano plot demonstrating the pattern of divergence and the fold induction of 
the 487 identified genes in the data set. 
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Supplemental Figure 4. CR affects gene signature pathways and 
networks associated with hepatic inflammation and metabolism. 
(A) IPA analysis identification of the Toll-like receptor pathway as a significantly 
downregulated pathway in CR mice compared to CTL; purple highlights indicate 
multiple targets confined within highlighted category and green color of 
intermediates indicates downregulated targets in CR compared to CTL. (B) IPA 
analysis identification of a network involved in lipid metabolism, carbohydrate 
metabolism, and cell growth and proliferation; green color indicates 
downregulated genes compared to CTL and red indicates upregulated genes. 
Darker color indicates greater up/downregulation. 
  
100 
 
  
Table 1. The 10 most significant canonical pathways in NT hepatic tissue comparing CR 
to CTL group. 
Ingenuity Canonical 
Pathways 
-log  
(p-
value) 
Ratio  
(numerical) 
Genes 
Hepatic Fibrosis 
& Hepatic Stellate Cell 
Activation 
7.46 17/117 (0.145) 
CCR5, VCAM1, ICAM1, COL4A1, 
COL12A1, KLF6, PDGFC, COL1A2, 
COL1A1, COL6A3, TIMP1, CYP2E1, 
CD14, SERPINE1, COL27A1, COL3A1, 
PDGFRB 
Atherosclerosis 
Signaling 7.43 
14/78 
(0.179) 
COL1A2, ITGB2, COL1A1, VCAM1, 
APOA4, ICAM1, IL1RN, CXCR4, CD36, 
LPL, SERPINA1, PLA2G7, PDGFC, 
COL3A1 
Altered T Cell and B 
Cell  
Signaling in 
Rheumatoid Arthritis 
7.09 11/48 (0.229) 
TLR2, HLA-A, IL1RN, TLR1, HLA-DMB, 
TLR8, HLA-DQA1, TLR7, Tlr13, 
HLA-DQB1, Tlr12 
Communication 
between  
Innate and Adaptive 
Immune Cells 
5.54 9/43 (0.209) 
CXCL10, TLR2, HLA-A, IL1RN, TLR1, 
TLR8, TLR7, Tlr13, Tlr12 
B Cell Development 5.11 5/11 (0.455) 
PTPRC, HLA-A, HLA-DMB, HLA-DQA1, 
HLA-DQB1 
Dendritic Cell 
Maturation 4.51 
12/101 
(0.119) 
TLR2, COL1A2, COL1A1, ICAM1, HLA-
A, IL1RN, TYROBP, TREM2, 
HLA-DMB, HLA-DQA1, HLA-DQB1, 
COL3A1 
TREM1 Signaling 4.09 8/50 (0.16) 
TLR2, ICAM1, TYROBP, TLR1, TLR8, 
TLR7, Tlr13, Tlr12 
LPS/IL-1 Mediated  
Inhibition of RXR 
Function 
4.07 15/166 (0.0904) 
ALDH1B1, SLC10A1, GSTA5, ALAS1, 
GSTT2/GSTT2B, Cyp2a12/Cyp2a22, 
CYP3A5, Gstm3, IL1RN, NR1I3, 
CYP7A1, FABP4, CD14, CYP2A6 
(includes others), CYP4A11 
Antigen Presentation 
Pathway 4.05 
5/17 
(0.294) 
HLA-A, HLA-DMB, HLA-DQA1, HLA-
DQB1, CD74 
 
Genes in bold are up-regulated 
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Table 2. The 11 most significant categories of disease/toxological function in NT hepatic tissue 
comparing CR to CTL group. 
Categories Disease/Function p-value Genes 
# of 
Molecules 
Liver 
Damage Injury of liver 9.35E-08 
Ccl2, CCR5, CD14, CDKN1A, 
CXCL10, CYP2E1, CYP7A1, 
HLA-A, IL1RN, ITGB2, KRT8, 
LIF, NT5E, SERPINA1, 
SERPINE1, SLC10A1, TLR2 
17 
Liver 
Damage Damage of liver 4.63E-07 
Ccl2, CCR5, CD14, CD44, 
CDKN1A, CXCL10, CYP2E1, 
CYP7A1, HLA-A, IL1RN, ITGB2, 
KRT8, LIF, NR1I3, NT5E, 
SERPINA1, SERPINE1, 
SLC10A1, TLR2 
19 
Liver 
Necrosis 
& Cell Death 
Necrosis of liver 5.21E-05 
CD14, CDKN1A, CXCL10, 
CYP2E1, CYP7A1, E2F1, 
GADD45B, IL1RN, ITGB2, KRT8, 
LGALS3, LIF, NR1I3, PTPRC, 
SERPINE1, TIMP1, TLR7, 
TYROBP 
18 
Liver 
Adhesion 
Adhesion of 
hepatocytes 2.27E-04 ICAM1, KRT8, VCAM1 3 
Liver 
Fibrosis Fibrosis of liver 2.57E-04 
COL1A1, COL1A2, HSPB1, 
IL2RG, LGALS3, PDGFC, 
PDGFRB, SERPINE1, TIMP1, 
Ccl2, CXCL10, LGALS3, 
PDGFC, PDGFRB, TIMP1 
15 
Liver 
Cholestasis 
Progressive familial 
intrahepatic 
cholestasis type 2 
4.45E-04 CYP7A1, SLC10A1, SLC10A2 3 
Liver 
Inflammation Inflammation of liver  
CD14, CD44, CYP2E1, HLA-A, 
IL1RN, ITGB2, LGALS3, PTPRC, 
SERPINE1, SLC10A1, SPI1, 
TLR7 
12 
Liver 
Necrosis 
& Cell Death 
Cell death of liver 
cells 1.22E-03 
CDKN1A, CXCL10, CYP2E1, 
CYP7A1, E2F1, GADD45B, 
IL1RN, ITGB2, KRT8, NR1I3, 
PTPRC, TIMP1, TLR7 
13 
Liver 
Cholestasis Hepatic cholestasis 1.62E-03 
CD68, CDKN1A, CYP7A1, 
RDH16, SLC10A1, SLC10A2, 
Slco1a1 
7 
Liver 
Hypertrophy Hypertrophy of liver 1.94E-03 CYP1A2, NR1I3 2 
Liver 
Steatosis Hepatic steatosis 4.79E-03 
Ccl2, CCR5, CD14, CYP2E1, 
INSIG2, NR1I3, PDGFC, TLR2 8 
Genes in bold are up-regulated. 
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Discussion 
Epidemiological and experimental data has long supported CR as a preventative 
intervention against numerous forms of cancer. CR studies have both focused on 
increasing longevity and delaying tumorigenesis in aged models (260), in 
improving disease free longevity (261), and limiting tumor progression (262). The 
present study demonstrates CR serves as a potent deterrent of hepatic 
carcinogenic promotion and progression. The results from this study both confirm 
previous reports demonstrating the longevity and anti-carcinogenic properties of 
CR and expand upon them, characterizing pathologic and transcriptome 
alterations induced by CR, thus providing mechanistic insights as to how CR 
elicits its oncogenic protection. 
Etiologies of liver cancer vary greatly between developed and developing 
countries. In developed regions of the world, obesity and subsequent NAFLD 
progression, has been well described to contribute to increase the risk of 
hepatocellular carcinoma and other liver cancers. In this study, CR significantly 
reduced steatotic burden, which strongly correlated with tumor risk. These data 
support previous studies showing that CR can reverse steatosis in obese rats 
(263). However, simple steatosis is not in and of itself pathologic. Instead, it is 
the subsequent damage resultant of continued neutral lipid accumulation in 
combination with derangements, which often accompany severe obesity, that 
play a pathologic role in hepatic cancer risk.  NASH, which is characterized by 
increased inflammation and cell damage greatly increases the risk in 
development of liver cancer (211, 263). In fact, population estimates from clinical 
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studies suggest NASH patients are twice as likely to develop cirrhosis when 
compared to hepatitis C patients (264). Demonstrating the importance of limiting 
progression of NAFLD, CR has been shown to curb the development of NASH 
(264). Corroborating this feature, CR mice had reduced lobular inflammation and 
hepatocyte ballooning. Resident hepatic macrophages known as Kupffer cells 
play an important role in mediating the response to liver injury (265). Additionally, 
the innate immune response plays an important role in mediating acute 
inflammation and hepatocyte damage (266). However, in NAFLD and NASH, 
chronic inflammation results in immune cell activation and infiltration, which 
promotes liver injury (267). Most notably, this aberrant response sensitizes toll-
like receptor signaling (268), which among other effects, increases production of 
inflammatory cytokines such as TNF-α, IL-12, and NF-kB (269). Histological and 
IHC analysis of CR mice exhibited reduced Kupffer cells, CD3+ T-cells, and 
neutrophils. Additionally, RNA-sequencing data showed that CR mice had 
reduced expression of genes encoding transcription factors, cytokines, and 
receptors involved in inflammation, liver damage, necrosis, and immune cell 
activation and infiltration. Thus, CR robustly prevents alterations of gene 
signatures, effectors, signaling networks, and subsequent disease development 
involved in the progression of NAFLD to liver cancer. 
A major consequence of progressive NASH, and risk factor for cirrhosis, is the 
development of fibrosis (264). Fibrosis is most notably accomplished through 
Kupffer cell and inflammatory cytokine activation of hepatic stellate cells. Located 
in the space of Disse, hepatic stellate cells serve as the primary source of 
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extracellular matrix proteins that contribute to fibrosis (270). TLR4 signaling 
initiates hepatic stellate cells to produce chemokines (CCL family), leading to 
recruitment of Kupffer cells, and increased TGF-β signaling (271). At the same 
time, TLR9 signaling initiates hepatic stellate cell collagen production, further 
progressing fibrosis (272). Hepatic stellate cell activation and proliferation were 
two major biologic functions found to be downregulated in CR mice through IPA 
of RNA-seq data. Additionally, TLR4 and TLR9 were both downregulated as 
were numerous CCL chemokines in CR mice, but only TLR9 and CCL1, 2, 20, 
and 22 met our cutoff parameters for statistical significance. This data supports 
previous reports investigating the effects of long-term CR on NF-kB signaling 
(273) and other inflammatory cytokines (274). The development of fibrosis and 
cirrhosis are established risk factors for the development of liver cancers 
including HCC (275). In accordance with this, IPA identified several genes 
related to the development of HCC with most downregulated genes in this 
network being positively associated with HCC (276), while those that were 
upregulated in CR mice are identified liver tumor suppressors (277). Within the 
hepatic tumor microenvironment, cell adhesion and migration in part driven by 
CD44, plays a critical role in the invasiveness of tumors (278). IPA determined 
CD44 mediated migration of pro-inflammatory molecules was universally 
repressed, identifying CR as a mitigator of cell damage leading to tumorigenesis. 
Collectively, this data highlights CR as a robust deterrent of signaling cascades 
and downstream biologic consequences associated with hepatic tumorigenic 
etiologies relevant to developed countries. 
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As a staple of the Mediterranean Diet, extra virgin OO elicits numerous health 
benefits. Previous studies have shown that the polyphenolic compounds in OO 
have anti-inflammatory and anti-oncogenic effects (279). However, these 
compounds are greatly enriched in extra virgin olive oil and variable amongst 
oils. Analyses of these polyphenolic compounds in our diets revealed 
undetectable levels suggesting poor phenolic content of our OO diet could 
potentially explain a lack of dietary effect on tumorigenesis. 
Independent evidence has shown that exercise and the MD reduce liver cancer 
risk, yet no studies have compared the synergistic effects of exercise and 
specific dietary constituents of the MD. Since mice have been documented to 
readily utilize running wheels (280), we used voluntary wheel running to test the 
effects of exercise on liver oncogenesis. Although mice initially utilized running 
wheels, after ~5 months activity levels did not exceed reported ambulatory 
movement (281). Lack of activity is further apparent when assessing body 
weight, which increased as running wheel utilization diminished. Given that 
phenotypic changes of Ex mice mirrored that of CTL mice, it is not surprising 
there were no differences in tumorigenesis.  Future studies of this nature should 
use controlled exercise interventions to account for individual variability in activity 
level and to ensure adherence of treatment for the duration of the study. 
Overall, these findings demonstrate CR as a robust deterrent of liver cancer and 
provide insight to possible mechanisms related to the pathology of liver cancer. 
Liver cancer is among the fastest growing cancers, especially in men, in 
developed countries and it remains among the world’s deadliest cancers with 
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mortality rates as high as 61% within 1 year of diagnosis. Given the limited 
treatment options, results here provide promise in describing CR or related 
dietary regiments as a therapeutic tool in cancer prevention and advance our 
understanding into the molecular mechanisms underlying the anti-oncogenic 
effects of CR.  
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Obesity continues to be one of the most prominent chronic health issues facing 
developed countries. Currently, over 70% of adults are considered overweight or 
obese while nearly 21% of children ages 12-19 are obese (282). More troubling, 
the proportion of children with obesity continues to increase with age suggesting 
this troubling trend will continue to plague Western societies for years to come 
with continued implementation of current therapeutic strategies. Economically, 
obesity continues to be one of the most expensive chronic conditions, costing 
Americans between $147 and $210 billion dollars annually in direct treatment 
costs associated with obesity and related diseases (283). However, the impact of 
obesity reaches beyond the bedside. Absenteeism resultant from obesity 
reached an estimated 450 million hours of lost work which translated into nearly 
$153 billion dollars in lost wages (284).  
Obesity has long been linked to numerous other pathologies including NAFLD. 
However, only in the past several years has obesity and NAFLD been identified 
as major risk factors for many different types of cancer. As a testament to this 
relationship, reduced cancer-related deaths are the primary factor contributing to 
the lower mortality in obese subjects that have undergone bariatric surgery (285). 
Moreover, the risk for HCC-related mortality is increased ~4.5 fold in obese 
males, more than any other type of cancer (29).  
Liver cancer has become a major health problem in developed countries, 
including the United States. Currently it is the fifth most common and one of the 
deadliest forms of cancer worldwide with more than 86% of cases resulting in 
death (286, 287).  The only viable option to treat liver cancer is partial liver 
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removal.  In the setting of obesity, partial liver removal/liver transplantation is 
often not indicated due to poor prognosis following surgery.  In addition to 
dramatically rising incidence of HCC, the mortality rate for NAFLD derived HCC 
is higher compared to other etiologic factors such as hepatitis viral infections, 
reaching as high as 61% mortality within 1 year of diagnosis (288). Furthermore, 
current treatment strategies are limited and largely palliative, thus demonstrating 
an urgent need for identification of new therapies. In contrast to overconsumption 
of calories, epidemiological and experimental data has long supported restriction 
of calories as a preventative intervention against numerous forms of cancer.  
Caloric restriction (CR) has historically been associated with what is known as 
continuous caloric restriction. Achieving continuous caloric restriction requires 
reducing macronutrient content daily, while remaining nutritionally sufficient. 
While initial studies investigated efficacy in prolonging life as well to 
prevent/delay tumor progression in animal models. Subsequent studies have 
investigated the percentage of CR as well as the macronutrient distribution of 
restriction. However, despite success in animal models, translational success of 
such interventions has been limited, in part due to the extreme difficulty in 
adhering to such rigorous dietary strategies long-term. Therefore, alternative 
strategies that result in restriction of energy intake in a noncontiguous manner 
have become an important evolution of this promising intervention. 
Unlike continuous energy restriction attributed to CR, Intermittent fasting (IF) is 
restricting caloric intake in a noncontiguous manner ranging from fasting every 
other day up to a week at a time; it too holds promise as a cancer deterrent. 
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Chrononutrition, a form of IF which has received recent investigational interest, 
elucidates the interaction between eating and circadian rhythms and how these 
interactions affect biological functions such as metabolism.  Current public health 
research tells us disturbing circadian rhythms (i.e. late night eating, night work 
shifts, insomnia, etc.) contributes not only to obesity (289, 290), but to liver 
cancer as well (291).  One approach to fasting that considers circadian rhythms 
is time-restricted feeding, an eating pattern which restricts food intake to a 
specific period of time, which has demonstrated promise in combating obesity in 
animal models.  To date, no evidence exists demonstrating the efficacy of time-
restricted feeding in liver cancer development in the setting of circadian rhythm 
dysfunction.  
For many nutrition health experts, the goal in curbing obesity related diseases is 
to identify obtainable and sustainable lifestyle interventions. However, dietary or 
lifestyle interventions have largely been shown to be ineffective due to lack of 
adherence (292).  Time-restricted feeding offers clinical promise because it is 
simple (requiring little to no expertise for execution), obtainable (requiring 
minimal lifestyle interventions) and sustainable (does not alter diet 
composition) over the long-term. 
In addition to identifying dietary strategies used to deter HCC, elucidating the 
molecular mechanisms that drive hepatic cancer are important events to be 
studied. Despite the clear relationship obesity and NAFLD have with cancer, the 
mechanisms underlying this relationship have not been fully elucidated. In the 
past decade, the field of cancer biology has seen an explosion of research into 
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the area of energy metabolism. A major emphasis of these studies has been on 
glucose and glutamine utilization and lipogenesis (64, 86, 93, 293), pathways 
that are robustly altered in cancer cells and that are largely conserved across 
different types of cancer. In addition, research on anabolic signaling pathways 
(Akt, mTOR, Ras/Raf, etc.) that are activated in response to excess calories and 
that are also increased in cancer cells have also been a major research focus. 
Catabolic metabolism has almost exclusively focused on glucose and amino acid 
metabolism. Lipolysis in cancer on the other hand, has primarily been studied in 
the context of cachexia (225, 294), leaving a dearth of knowledge in this area of 
metabolism. However, with the recent discoveries that growth factors suppress 
ATGL (154) and that catecholamine induced lipolysis ablates mTORC1 signaling 
in adipose tissue (227), there is a renewed focus on oncogenic metabolism. 
Thus, with anabolic signaling implicated in the pathophysiology of oncogenic 
events and development of liver cancer (228, 259, 295, 296), further investigation 
is warranted in identifying the molecular mechanism underlying ATGL and 
lipolysis in liver cancer.  
We have recently shown that ATGL expression is driven by FoxO 
proteins, which largely drive pathways antagonistic to mTOR (220).  Our 
laboratory has also shown that ATGL induces a signaling network that promotes 
FA oxidative metabolism and mitochondrial biogenesis while attenuating glucose 
utilization (109, 297).  Further interrogation revealed that ATGL promotes these 
pathways thought its induction of the protein deacetylase SIRT1, which in turn 
regulates a downstream transcriptional network including PPAR-a, PGC-1a and 
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FoxO proteins known to govern oxidative metabolism, mitochondrial function and 
promote oxidative stress resistance (224).  This transcriptional network, 
especially FoxO proteins, is known to have anti-proliferative effects (228, 298–
300). Thus, future studies will want to explore the mechanistic link between 
ATGL as a mediator in tumor suppression as well as its role in explaining the 
benefits described from dietary interventions such as caloric restriction or time 
restricted feeding. Such results will help to extrapolate causal links in dietary 
intervention studies as well as providing new therapeutic avenues in the 
prevention and treatment of liver cancer. 
In summary, fasting metabolism perpetuated through dietary intervention or 
modulation of ATGL demonstrates significant promise in curbing a rapidly 
growing and deadly form of cancer in developed countries such as the United 
States. Future research will be needed to identify dietary and lifestyle 
interventions that are sustainable if we are to combat obesity related pathologies 
such as HCC. Deeper insight into the mechanism that drive these alterations will 
provide crucial insight that will help identify key molecular signatures of an 
otherwise largely understudied etiology of liver cancer. Information gained from 
such studies may help to provide new clinical tools through lifestyle modification 
or therapeutics.  
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